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1.Abbreviations  
A Adenine 
AA Amino acid 
ABLV Australian bat lyssavirus 
ARAV Aravan virus 
BBLV Bokeloh bat lyssavirus 
C Cytosine 
CDC Centers for Disease Control and Prevention 
CNS Central nervous system 
DNA Deoxyribonucleic acid 
dRIT Direct rapid immunohistochemical test 
DUVV Duvenhage virus 
EBLV-1 European bat lyssavirus 1 
EBLV-2 European bat lyssavirus 2 
f.p. Footpad 
FAO Food and Agriculture Organization of the United Nations 
FAT Fluorescence antibody test 
FITC Fluorophore conjugated 
FLI Friedrich-Loeffler-Institut 
G Guanine 
GARC Global Alliance for Rabies Control 
GBLV Gannoruwa bat lyssavirus 
Gln Glutamine 
His Histidine 
i.m. Intramuscular 
i.n. Intranasal 
ICTV International Committee on Taxonomy of Viruses 
IFN Interferon 
IGR Intergenic region 
IKOV Ikoma virus 
indels Insertions and deletions 
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IRKV Irkut virus 
kb Kilobase 
KHUV Khujand virus 
LBV Lagos bat virus 
LFD Lateral flow device 
LLEBV Lleida bat lyssavirus 
MIT Mouse inoculation test 
MOKV Mokola virus 
mRNA Messenger ribonucleic acid 
N Any base 
nAchR Nicotinic acetylcholine receptor 
NASBA Nucleic acid sequence based amplification 
NCAM Neuronal cell adhesion molecule 
nm Nanometre 
nt Nucleotide 
OIE World Organization for Animal Health 
p75NTR Low affinity nerve growth factor 
PEP Post-exposure prophylaxis 
RABV Rabies virus 
RNA Ribonucleic acid 
RNase Ribonuclease 
RNP Ribonucleoprotein 
RTCIT Rabies tissue culture infection test 
RT-LAMP Reverse transcription loop mediated isothermal amplification 
RT-PCR Reverse transcription polymerase chain reaction 
s.c. Subcutaneous 
SHIBV Shimoni bat virus 
STAT Signal transducer and activator of transcription 
T Thymine 
TIS Transcription initiation signal 
TTS Transcription termination signal 
UTR Untranslated region 
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WCBV West Caucasian bat virus 
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2.Introduction 
Rabies, caused by lyssaviruses, is a zoonotic disease responsible for an estimated 59000 
human deaths per year and is classified as a neglected zoonotic disease by the World Health 
Organization (WHO). Since rabies is almost always fatal once clinical signs develop, 
preventive vaccination of risk groups or prompt application of post exposure prophylaxis is 
of utmost importance. In most of Europe, rabies has been eliminated in terrestrial animals, 
but is still present in bats. In order to understand bat rabies epidemiology, dynamics and 
possible emergence, bat rabies surveillance is performed in parts of Europe including 
Germany and five bat lyssaviruses have been detected so far. European bat lyssavirus 1 
(EBLV-1) was identified as the main cause of bat rabies in Europe. For this lyssavirus, spill-
over infections in other mammals including humans have been recorded.  
Rabies in terrestrial mammals is caused by rabies virus (RABV). Dogs are the main source for 
human infection, with dog-mediated human rabies being endemic especially in Asia and 
Africa. Unfortunately, rabies surveillance, as the basis for control and elimination, is 
hampered for various reasons including challenges in rabies diagnosis. For this reason 
alternative test methods for rabies diagnosis in the form of point of care tests, were 
developed, e.g. lateral flow devices (LFDs).  
This thesis focuses on aspects of lyssavirus surveillance and pathogenicity in order to clarify 
further the potential impact of bat lyssaviruses on human health in Europe. As for the latter, 
the pathogenicity of EBLV-1 isolates with certain genetic variations was assessed. Also, 
previously established enhanced passive bat rabies surveillance in Germany was continued. 
Furthermore, to facilitate and strengthen surveillance efforts particularly in the developing 
world, commercially available LFDs for rabies diagnosis were evaluated. 
Introduction 
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3.Literature review 
3.1. History of rabies with focus on Europe 
The over 4200 years old Eshnunna code contains the first known record of a disease 
resembling rabies (Baer et al., 1996). In the next 1500 years there is hardly any mention of 
rabies, followed by a period (ca. 5th BC to 5th AC) with many records, describing the 
symptoms, transmission, preventive measures, as well as suggesting cures (Neville, 2004). 
Progress concerning rabies was only made in the 19th century with first pathogenesis 
studies (Jackson, 2013) and subsequent development of the first rabies vaccine by Louis 
Pasteur. Pasteur discovered that through repeated inoculation of desiccated nerve tissue 
from rabid animals, rabies infection could be prevented. The first person who successfully 
received the vaccine was a boy named Joseph Meister, who had been severely bitten two 
days earlier by a rabid dog (Suzor and Pasteur, 1887). This so called nerve tissue vaccine was 
further enhanced to reduce unwanted side effects and used in many countries for several 
decades (Jackson, 2013). 
A vaccine for dogs was developed in the early 1920´s (Baer, 1975a). Previously, the only 
control measures for elimination of dog rabies were veterinary control measures, e.g. dog 
movement restriction, muzzling and elimination of stray dogs, leading to successful 
elimination in some countries, i.e. Prussia, Denmark, Norway and Sweden (Tarantola, 2017). 
Mass vaccination of dogs resulted in elimination of dog-mediated rabies in most of Europe 
by the mid of the last century. Great progress was also made in the Americas, resulting in the 
disappearance of dog-mediated rabies in many countries (Vigilato et al., 2013, Velasco-Villa 
et al., 2017).  
Parallel to the control of the disease in dogs, terrestrial rabies in wildlife, i.e. foxes, came 
into focus as a source of rabies infections. In Europe, fox mediated rabies emerged in the 
1940´s and spread across most of the continent within a few decades, representing new 
challenges in rabies control (Müller and Freuling, 2011). These were met in the 1970´s with 
the development of orally applicable vaccines and corresponding baits, and the 
implementation of oral rabies vaccination, which led to the elimination of terrestrial rabies 
in Western and Central Europe (Müller et al., 2012). 
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Although the association of rabies with dogs has been known for millennia, it was only much 
later recognized that bats also transmit rabies. In 1930´s an outbreak of rabies occurred and 
vampire bats were identified as the source of infection (Baer, 1975b, Pawan, 1936).  
In Europe, the first bat rabies case was discovered in 1954 in Hamburg, Germany, when a 
boy was bitten by a bat, which subsequently tested positive for rabies. The child received 
post exposure treatment and survived (Mohr, 1957). Between 1954 and 1989 a total of 4705 
bats were tested for rabies in Europe of which 379 were positive for rabies (Kappeler, 1989). 
Serotyping of bat rabies isolates in Europe showed that they did not belong to the known 
classical rabies virus (RABV), but were similar to Duvenhage virus (Fekadu et al., 1988a, 
Schneider et al., 1985). In 1988, a distinction between Duvenhage virus and European 
lyssaviruses was made (Dietzschold et al., 1988), followed by their separation into two 
serotypes/biotypes, EBL1 and EBL2 (now called EBLV-1 and EBLV-2) (King et al., 1990, Hirose 
et al., 1990, Bourhy et al., 1992). The discovery of other bat lyssaviruses in Europe followed, 
i.e. West Caucasian bat lyssavirus in 2002, Bokeloh bat lyssavirus in 2010 and Lleida bat 
lyssavirus in 2013 (Freuling et al., 2011, Arechiga Ceballos et al., 2013, Botvinkin et al., 2003). 
3.2. Lyssaviruses 
The word lyssa is of ancient Greek origin and translates as madness (Baer, 1975b). It is 
suggested that its root is either lysis (loosing – loss of rational faculties), lykos (wolf) or lud 
(violent) (Jackson, 2013, Neville, 2004). A lyssavirus infection results in rabies, a zoonotic 
disease, which is almost always fatal once clinical signs develop (Taylor and Nel, 2015). 
3.2.1. Virus Taxonomy 
The term “lyssaviruses” comprises all viruses of the Genus Lyssavirus, which belongs to the 
family Rhabdoviridae of the order Mononegavirales. Originally, lyssaviruses were separated 
into serotypes or genotypes. Following taxonomic guidelines, lyssaviruses were then 
classified into species according to species demarcation criteria that include homology of the 
viral genomes (King et al., 2012). Currently, the genus Lyssavirus comprises 16 species, of 
which 14 are officially recognized by the International Committee on Taxonomy of Viruses 
Literature review 
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(ICTV) (King et al., 2012). Two lyssaviruses, i.e. Lleida bat lyssavirus (LLEBV) and Gannoruwa 
bat lyssavirus (GBLV), although approved by the executive committee still await ratification 
from the ICTV (Table 1) (International Committee on Taxonomy of Viruses 2017). 
Furthermore, two isolations of a novel lyssavirus were made from Japanese house bats 
(Pipistrellus abramus) in Taiwan in November 2016 and April 2017, although this virus does 
not have an assigned name yet (Shu-min, 2016, Chatterjee, 2017). 
Lyssaviruses can be further divided into two phylogroups, based on their phylogenetic, 
immunologic and pathogenic properties (Badrane et al., 2001). Phylogroup 1 comprises most 
lyssavirus species, i.e. RABV, EBLV-1, EBLV-2, BBLV, ABLV, GBLV, IRKV, ARAV, KHUV and 
DUVV, whereas phylogroup 2 includes three African lyssavirus species, i.e. LBV, MOKV and 
SHIBV (Table 1) (Kuzmin et al., 2005, Kuzmin et al., 2010, Badrane et al., 2001). IKOV, WCBV 
and LLEBV do not belong to either phylogroup and it has not been determined yet if they 
group together in a third phylogroup, or if a fourth phylogroup comprising IKOV and LLEBV 
should be established (Table 1) (Arechiga Ceballos et al., 2013, Banyard et al., 2014a). This 
separation into different phylogroups is very important, as there is no cross neutralization 
between viruses of the different groups. Therefore, commercial rabies vaccines, which are 
based on RABV, elicit protection against lyssaviruses of phylogroup 1, but do not reliably 
protect against lyssaviruses of the other phylogroups (Fekadu et al., 1988b, Badrane et al., 
2001, Malerczyk et al., 2014, Brookes et al., 2005, Malerczyk et al., 2009). 
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Table1: Members of the genus lyssavirus (modified from Gunawardena et al., 2016, Banyard 
et al., 2014a), including phylogroup, reservoir and distribution. GBLV and LLEBV have no 
assigned species name, since they have not yet been approved by the ICTV. Asterisks 
indicate that the reservoir has not been confirmed, due to the limited number of isolations 
of the respective lyssaviruses. 
P
h
yl
o
gr
o
u
p
V
ir
u
s 
n
am
e
Sp
ec
ie
s 
n
am
e
A
b
b
re
vi
at
io
n
R
es
er
vo
ir
D
is
tr
ib
u
ti
o
n
R
ab
ie
s 
vi
ru
s
R
a
b
ie
s 
ly
ss
a
vi
ru
s
R
A
B
V
C
h
ir
o
p
te
ra
, 
C
a
rn
iv
o
ra
w
o
rl
d
w
id
e 
ex
ce
p
t 
A
u
st
ra
lia
 a
n
d
 A
n
ta
rc
ti
ca
Eu
ro
p
ea
n
 b
at
 ly
ss
av
ir
u
s 
1
Eu
ro
p
ea
n
 b
a
t 
1
 ly
ss
a
vi
ru
s
EB
LV
-1
C
h
ir
o
p
te
ra
 
Eu
ro
p
e
Eu
ro
p
ea
n
 b
at
 ly
ss
av
ir
u
s 
2
Eu
ro
p
ea
n
 b
a
t 
2
 ly
ss
a
vi
ru
s
EB
LV
-2
C
h
ir
o
p
te
ra
 
Eu
ro
p
e
B
o
ke
lo
h
 b
at
 ly
ss
av
ir
u
s
B
o
ke
lo
h
 b
a
t 
ly
ss
a
vi
ru
s
B
B
LV
C
h
ir
o
p
te
ra
 
Eu
ro
p
e
A
u
st
ra
lia
n
 b
at
 ly
ss
av
ir
u
s
A
u
st
ra
lia
n
 b
a
t 
ly
ss
a
vi
ru
s
A
B
LV
C
h
ir
o
p
te
ra
 
A
u
st
ra
lia
Ir
ku
t 
vi
ru
s
Ir
ku
t 
ly
ss
a
vi
ru
s
IR
K
V
C
h
ir
o
p
te
ra
*
A
si
a
A
ra
va
n
 v
ir
u
s
A
ra
va
n
 ly
ss
a
vi
ru
s
A
R
A
V
C
h
ir
o
p
te
ra
*
A
si
a
K
h
u
ja
n
d
 v
ir
u
s
K
h
u
ja
n
d
 ly
ss
a
vi
ru
s
K
H
U
V
C
h
ir
o
p
te
ra
*
A
si
a
G
an
n
o
ru
w
a 
b
at
 ly
ss
av
ir
u
s
-
G
B
LV
C
h
ir
o
p
te
ra
 
A
si
a
D
u
ve
n
h
ag
e 
vi
ru
s
D
u
ve
n
h
a
g
e 
ly
ss
a
vi
ru
s
D
U
V
V
C
h
ir
o
p
te
ra
 
A
fr
ic
a
La
go
s 
b
at
 v
ir
u
s
La
g
o
s 
b
a
t 
ly
ss
a
vi
ru
s
LB
V
C
h
ir
o
p
te
ra
 
A
fr
ic
a
M
o
ko
la
 v
ir
u
s
M
o
ko
la
 L
ys
sa
vi
ru
s
M
O
K
V
Sh
re
w
s 
(C
ro
ci
d
u
ra
 s
p
.)
, s
m
al
l 
ro
d
en
t 
(L
o
p
yh
ro
m
ys
 s
ik
a
p
u
si
)*
A
fr
ic
a
Sh
im
o
n
i b
at
 v
ir
u
s
Sh
im
o
n
i b
a
t 
ly
ss
a
vi
ru
s
SH
IB
V
C
h
ir
o
p
te
ra
*
A
fr
ic
a
W
es
t 
C
au
ca
si
an
 b
at
 v
ir
u
s
W
es
t 
C
a
u
ca
si
a
n
 b
a
t 
ly
ss
a
vi
ru
s
W
C
B
V
C
h
ir
o
p
te
ra
*
Eu
ro
p
e
Ll
ei
d
a 
b
at
 ly
ss
av
ir
u
s
-
LL
EB
V
C
h
ir
o
p
te
ra
*
Eu
ro
p
e
Ik
o
m
a 
vi
ru
s
Ik
o
m
a
 L
ys
sa
vi
ru
s
IK
O
V
A
fr
ic
an
 c
iv
et
 (
C
iv
et
ti
ct
is
 
ci
ve
tt
a
)*
A
fr
ic
a
3
-421
Literature review 
11 
3.2.2. Virus structure and viral genome 
As a member of the Rhabdoviridae, lyssavirus virions are rod- or bullet-shaped (rhabdos – 
rod) and measure between 100-250nm in length with a diameter of roughly 80 nm 
(Matsumoto, 1962, Davies et al., 1963).  
The ribonucleoprotein (RNP) comprises the viral genomic ribonucleic acid (RNA) 
encapsidated by the nucleoprotein, while the viral RNA-dependent RNA-polymerase and the 
phosphoprotein are associated with the RNP, forming together the core structure of the 
virion (Davis et al., 2015). The RNP is surrounded by a host derived membrane with the 
matrix protein forming a bridge between the virus membrane and the core (Mebatsion et 
al., 1999). The surface of the virus particle is covered by glycoprotein homotrimers, the only 
surface protein of the virus (Gaudin et al., 1992). 
Figure 1: Structure of the lyssavirus type species RABV depicted as schematic illustration and 
electron microscopic pictures. G: glycoprotein; L: RNA-polymerase; M: matrix protein; N: 
nucleoprotein; P: phosphoprotein. (© Friedrich-Loeffler-Institut Insel Riems, Dr. H. Granzow, 
M. Jörn)  
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3.2.2.1. Viral RNA 
The lyssavirus genome consists of a ca. 12 kilobases (kb) long single stranded negative sense 
RNA (Marston et al., 2007). It carries the genes for the five virus proteins in a strictly 
conserved order (3´ – nucleoprotein gene – phosphoprotein gene – matrix protein gene – 
glycoprotein gene – RNA-polymerase gene – 5´) (Tordo et al., 1986a). The genes are 
separated by intergenic regions. At the termini of the genomic RNA noncoding leader and 
trailer sequences are present (Wunner and Conzelmann, 2013). The length of the intergenic 
regions (IGR) are 2 nucleotides (nts) between the nucleoprotein gene and the 
phosphoprotein gene, 5nts between the phosphoprotein gene and the matrix protein gene 
as well as between the matrix protein gene and the glycoprotein gene and 19nts to 24nts 
between the glycoprotein gene and the RNA-polymerase gene. Exceptions are the IGRs of 
MOKV and WBCV between the matrix protein gene and the glycoprotein gene, and between 
the glycoprotein gene and the RNA-polymerase gene, which are significantly longer 
(Marston et al., 2007). The lengths of the IGRs influence downstream transcription (Finke et 
al., 2000). Each gene starts with a transcription initiation signal (TIS) (5´-AACAYYNCT-3´; A: 
Adenine, C: Cytosine, T: Thymine, Y: C or T, N: any base) and ends with a transcription 
termination polyadenylation signal (TTS) (5´-WGAAAAAAA-3´; W: A or T, G: Guanine) 
respectively (Marston et al., 2007). The length of the untranslated regions (UTRs), 
comprising the regions between the TIS and the start codon for translation and between the 
stop codon and the TTS, vary. The 3`-UTRs of the virus genes are shorter (20-30nts) 
compared to the 5´-UTRs (100-500nts) (Wunner and Conzelmann, 2013). The 5`-UTR of the 
glycoprotein gene, also called pseudogene, is particularly long and believed to be the 
remnant of a former 6th gene (Tordo et al., 1986b).  
3.2.2.2. Viral proteins 
The nucleoprotein is the most conserved lyssavirus protein. The high conservation of the 
amino acid (AA) sequence is most likely due to its function in encapsidation of the viral RNA, 
for which interaction sites need to be conserved. Through the formation of the RNP, the 
nucleoprotein protects the viral genome from host ribonucleases (RNases) (Albertini et al., 
2011). Serotyping of lyssavirus isolates and subsequent division in serotypes/biotypes was 
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routinely performed with monoclonal anti-nucleoprotein antibodies (Schneider, 1982, 
Dietzschold et al., 1988, King and Crick, 1988, Bourhy et al., 1992, Hirose et al., 1990). Since 
demarcation of lyssaviruses switched to genotypes and species based on nucleotide 
sequences, the corresponding nucleoprotein gene is now preferably used for sequence 
comparisons (Nadin-Davis and Real, 2011). Furthermore, due to the conserved AA sequence 
of nucleoprotein and its abundance in host cells as the first transcribed protein, anti-
nucleoprotein antibodies are commonly used in lyssavirus antigen detection assays (OIE, 
2012). The phosphoprotein is, in contrast to the nucleoprotein, the least conserved of the 
lyssavirus proteins (Marston 2007). The phosphoprotein is dimeric and has multiple 
functions in RNA replication, virus assembly and as an interferon antagonist. As a non-
catalytic cofactor of the viral polymerase, the phosphoprotein stabilizes the former and 
places the phosphoprotein – RNA-polymerase complex on the viral RNA (Wunner and 
Conzelmann, 2013). Furthermore, the phosphoprotein prevents the aggregation and 
nonspecific binding of newly synthesized nucleoprotein to cellular RNA, by acting as a 
chaperone (Liu et al., 2004, Yang et al., 1998) . The phosphoprotein is also a major interferon 
(IFN) antagonist, by interfering with gene expression of IFN, and STAT protein signalling 
caused by IFN (Rieder and Conzelmann, 2011). The matrix protein plays an important role in 
virus assembly and budding. It is responsible for the bullet shaped structure of the virion, by 
condensing the RNP into its helical structure. Attachment of the core structure to 
glycoprotein in the host membrane is also mediated by the matrix protein, therefore the 
matrix protein is essential for budding of virus particles (Mebatsion et al., 1999). 
Furthermore, the matrix protein inhibits transcription and promotes RNA replication, 
regulating the balance between the two processes (Finke et al., 2003). On the host side, the 
matrix protein can inhibit RNA translation and induces apoptosis (Gholami et al., 2008, 
Komarova et al., 2007, Kassis et al., 2004).  
The glycoprotein is probably the most extensively analysed protein since it is an important 
pathogenicity determinant as well as an immunogen (Wunner and Conzelmann, 2013). It is a 
transmembrane protein and consists of a carboxyl-terminal domain (endodomain), a 
transmembrane domain and an ectodomain as well as an amino-terminal 19AA signal 
peptide, which is cleaved of and acts as a membrane insertion signal during protein 
maturation (Anilionis et al., 1981). As the only viral surface protein glycoprotein enables 
attachment of virus particles to host cell membranes by binding to specific host cell 
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receptors. After endocytosis of the virus particle, the glycoprotein mediates pH dependent 
fusion of virus and endosomal membrane (Gaudin et al., 1993). Furthermore, it facilitates 
retrograde axonal transport (Mazarakis et al., 2001). The glycoprotein is glycosylated at one 
or more sites in the ectodomain, with one glycosylation site known to be conserved in at 
least seven lyssavirus species (Badrane et al., 2001). Glycosylation is essential for the 
intracellular transport of glycoprotein and important for its antigenicity (Shakineshleman et 
al., 1992). Similar to matrix protein, glycoprotein can also induce apoptosis of the host cell 
(Prehaud et al., 2003, Faber et al., 2002, Morimoto et al., 1999). 
The RNA-dependent RNA-polymerase is by far the largest of the lyssavirus proteins. It forms 
the enzymatic component of the polymerase complex and is essential for transcription and 
replication (Wunner and Conzelmann, 2013). No efficient in vitro system exists for RABV 
messenger RNA (mRNA) synthesis, but the RABV RNA-polymerase displays great sequence 
similarity to the RNA-polymerase of another member of the Rhabdoviridae, Vesicular 
stomatitis virus (VSV) (Villarreal and Holland, 1974, Kawai, 1977, Tordo et al., 1988). 
Therefore, it is presumed that the functions of the two RNA-polymerases are similar and 
most of the functions of RABV RNA-polymerase were determined by studying VSV RNA-
polymerase. The RNA-polymerase initiates transcription of the virus genome, is responsible 
for nucleotide polymerization and has furthermore important enzymatic functions in mRNA 
capping, methylation and 3´-polyadenylation. RNA-polymerase also displays protein kinase 
activity and is responsible for phosphorylation of phosphoprotein in transcriptional 
activation (Banerjee, 1987). Recently the catalytic activity of the RNA-polymerase in mRNA 
capping was shown for rabies virus (Ogino et al., 2016). 
 
3.2.3. Replication cycle 
Lyssavirus infection starts with glycoprotein mediated attachment of the virus to the host 
cell. Various host cell receptors are known to play a role in virus attachment. These include 
the nicotinic acetylcholine receptor (nAchR), the neuronal cell adhesion molecule (NCAM) 
and the low affinity nerve growth factor (p75NTR), although none of these receptors were 
proven to be essential for virus infection (Lentz et al., 1982, Reagan and Wunner, 1985, 
Thoulouze et al., 1998, Tuffereau et al., 1998, Jackson and Park, 1999). Following attachment 
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the virus particle is engulfed into lysosomes and the core structure of the virus particle is 
released by fusion of the virus envelope with the endosomal membrane. This fusion process 
is triggered by a low pH within the endosome (Superti et al., 1984). Transcription and 
replication probably takes place within inclusion bodies, in neuronal cells termed Negri 
bodies, in the cytoplasm of the host cell (Lahaye et al., 2009). RNA transcription is initiated 
by the polymerase at the 3´-end of the genome, starting at the TIS and terminated at the TTS 
where the polymerase stutters to and fro for polyadenylation (Barr et al., 1997). Afterwards 
it dissociates from the template RNA and re-associates at the next TIS. Re-association of the 
polymerase does not always occur, its likelihood depending on the length of the IGR (Finke 
et al., 2000). Therefore, the lyssavirus genes downstream of the viral genome are less 
frequently transcribed, resulting in a negative transcription gradient (Banerjee, 1987). High 
levels of matrix protein modulate the switch from RNA transcription to replication (Finke et 
al., 2003). In the replication mode, full-length positive-sense RNA antigenomes are produced 
by the polymerase, which then act as templates for new full-length negative-sense RNA 
production (Banerjee, 1987). The RNP, associated with phosphoprotein and RNA-polymerase 
form new core structures of the virions, which are then tightly condensed into their helical 
structures by matrix protein (Mebatsion et al., 1999). Budding of the virus particles is 
facilitated by the interaction of matrix protein with glycoprotein, which is inserted into the 
host cell membrane following maturation in the endoplasmic reticulum (Schnell et al., 2010). 
3.3. Rabies disease 
The Latin word rabies is probably derived from the old Sanskrit word rabhas (“to do 
violence”), whereas the German word “Tollwut” originated from Indo-Germanic Dhvar (to 
damage) and middle German wuot (rage) (Baer, 1975b). Rabies is responsible for an 
estimated 59000 human deaths per year and is classified by the WHO as a neglected 
zoonotic disease (Hampson et al., 2015, WHO, 2013b). In 2015, the United Nations drafted 
an agenda with the goal to end neglected tropical diseases by 2030 (United Nations, 2016). 
Three month later a joint collaboration of the WHO, the OIE, the Food and Agriculture 
Organization of the United Nations (FAO) and the Global Alliance for Rabies Control (GARC) 
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developed a global framework for the elimination of dog-mediated human rabies by 2030 
(WHO & OIE, 2016). 
3.3.1. Pathogenesis 
Lyssaviruses are transmitted through the inoculation of virus containing saliva via bites or 
scratches of the infected animals (Fekadu et al., 1982). It is believed that prior to 
neuroinvasion lyssaviruses replicate in the muscle at the site of inoculation. This is supported 
by the ability of lyssaviruses to replicate in denerved muscle tissue in vivo and to bind to 
nAchRs at the postsynaptic membranes (Lafon, 2005, Charlton et al., 1997, Charlton and 
Casey, 1981, Murphy et al., 1973a). This replication step is not mandatory and immediate 
infection of neurons following inoculation can occur (Shankar et al., 1991, Coulon et al., 
1989). Neuroinvasion starts with the infection of primary motor neurons at the presynaptic 
membranes via NCAM, p75NTR or other unknown receptors (Lafon, 2005). Once inside the 
neuron, virus particles reach the neuronal cell body via retrograde axonal transport along 
the microtubular motor network, where replication takes place (Ceccaldi et al., 1989, 
Bijlenga and Heaney, 1978). Afterwards transportation and budding from another synapse 
occur, resulting in the distribution of the virus in the central nervous system (CNS) (Ugolini, 
2011). At the same time the virus undergoes a centrifugal spread along neurons to the 
peripheral organs (Jackson et al., 1999, Murphy et al., 1973b). In the salivary glands, budding 
of virus particles from mucogenic acinar cells occurs, followed by shedding of the virus with 
the saliva (Dierks et al., 1969, Fekadu et al., 1982). Lyssavirus infection results in 
encephalomyelitis, although only little histopathological changes are observed (Yan et al., 
2001, Murphy, 1977). 
3.3.2. Clinical picture 
For human rabies, disease progression can be divided into five stages according to 
symptoms, i.e. the incubation period, the prodrome, the acute neurological phase, coma and 
death (Hemachudha et al., 2002). The incubation periods following exposure are usually 
between one and two months. Very long incubation periods of up to several years following 
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a bite have also been observed, rendering the connection of bite history to subsequent 
clinical symptoms difficult (Hemachudha et al., 2002, Smith et al., 1991, Rupprecht et al., 
2002). The incubation period ends with the prodromal phase, where first unspecific clinical 
symptoms appear, e.g. fever or local symptoms like burning, numbness, tingling or itching 
(Hemachudha, 1994). The acute neurological phase can manifest either as furious 
(encephalitic) rabies or as paralytic rabies (Hemachudha et al., 2002). The three symptoms 
characteristic for furious rabies are fluctuating consciousness, phobic spasms and signs of 
autonomic dysfunctions including piloerection and hypersalivation (Hemachudha, 1994). 
Roughly a third of the rabies patients develop paralytic rabies, which usually starts with 
weakness in the bitten extremity, progressing to other parts of the body (Hemachudha, 
1994). Here, phobic spasms are observed in roughly half of the patients. The patients then 
lapse into a coma and subsequently die, in most cases due to circulatory insufficiency, 
manifesting as arrhythmia or hypotension (Hemachudha, 1994). The average survival time, 
after the onset of clinical symptoms, is two weeks and shorter for patients with furious 
rabies than for patients with paralytic rabies (Hemachudha et al., 2002, Mitrabhakdi et al., 
2005). 
Similar to humans the initial clinical signs in animals are often unspecific and include 
lethargy, diarrhoea and vomiting. This is followed by a rapid deterioration, where 
behavioural changes in the form of tameness up to aggressiveness, parasthesiasis and 
autonomic dysfunctions, e.g. hypersalivation, can occur. Other neurologic dysfunctions 
include tremors, seizures, paresis and paralysis. Death is caused most likely by severe 
autonomic dysfunctions (Hanlon, 2013). 
3.3.3. Pathogenicity 
Although rabies disease almost always results in death once clinical signs develop, not every 
lyssavirus infection leads to the development of clinical signs (Taylor and Nel, 2015). 
Especially bats seem to be able to clear the virus before it reaches the CNS and develop 
neutralizing antibodies (Kuzmin and Rupprecht, 2015). The pathogenicity of lyssavirus 
isolates depends on various factors, including the inoculation dose, inoculation route, as well 
as the animal species, age and immune status (Banyard et al., 2014b, Coulon et al., 1994, 
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Jackson and Fu, 2013). Furthermore, pathogenicity depends on the lyssavirus species and 
the respective isolate (Kgaladi et al., 2013, Badrane et al., 2001, Cunha et al., 2010, Perrin et 
al., 1996). Differences in the pathogenicity of isolates belonging to one lyssaviruses species 
were found for LBV and RABV, and are most likely linked to genetic differences of the 
respective isolates (Kgaladi et al., 2013, Cunha et al., 2010, Markotter et al., 2009a). Sites in 
the genome or the respective protein that have an influence on the properties of a virus, so 
called pathogenicity determining sites, have been identified for RABV with the help of 
reverse genetics (Virojanapirom et al., 2016, Tuffereau et al., 1989, Rieder et al., 2011). They 
include not only amino acid exchanges in the respective proteins but also nucleotide 
exchanges in UTRs and IGRs (Finke et al., 2000, Conzelmann et al., 1990, Virojanapirom et 
al., 2016). Unfortunately, not many reverse genetic systems exist for other lyssaviruses, and 
knowledge about pathogenicity determinants in field virus isolates is poor (Orbanz and 
Finke, 2010, Nolden et al., 2016). 
3.3.4. Vaccination and post exposure prophylaxis 
Vaccination against rabies is the foremost tool for preventing, controlling and eliminating 
the disease in terrestrial mammals and humans. In human medicine parenteral vaccination 
against rabies is recommended for certain risk groups, e.g. laboratory workers, veterinarians, 
animal handlers and bat conservationists (WHO, 2013a). Post-exposure prophylaxis (PEP) 
after contact with a rabid or rabies suspected animal includes local wound treatment, 
vaccination and administration of rabies immunoglobulin. The extent of PEP, especially 
concerning immunoglobulin administration, should be assessed for every case and depends 
on several factors (WHO, 2013b), including the epidemiological situation, the clinical 
features and vaccination status of the animal, the severity of the exposure, and the 
vaccination history of the patient (WHO, 2013a). There is no treatment proven to prevent 
death once clinical signs develop and reports of patients surviving rabies are very rare 
(Rupprecht et al., 2017). 
Two vaccination strategies for terrestrial mammals exist, which are parenteral vaccination 
with inactivated or live recombinant vectored RABV vaccines and oral vaccination with live 
attenuated RABV vaccines (WHO, 2013a). Parenteral vaccination is performed for domestic 
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animals and is the main tool for the control and elimination of dog rabies (Fooks et al., 
2014). Oral vaccination, performed in terrestrial wildlife populations, can successfully control 
and eliminate rabies, as exemplified by the elimination of fox rabies in most of Europe 
(Freuling et al., 2013a). Due to the residual pathogenicity of oral vaccines, sporadic vaccine 
induced rabies cases have occurred (Vuta et al., 2016, Robardet et al., 2016, Hostnik et al., 
2014, Müller et al., 2009, Fehiner-Gardiner et al., 2008). 
3.4. Rabies epidemiology 
3.4.1. Terrestrial rabies 
Terrestrial rabies, i.e. RABV in non-bat reservoirs, is endemic on all continents, except 
Australia and Antarctica and has been eliminated in Western and Central Europe (Müller et 
al., 2015, Sparkes et al., 2016, Nel and Markotter, 2007). The last rabies case in terrestrial 
wildlife in Germany was reported in 2006, and in 2008 Germany self-declared a “rabies free” 
status according to the standards by the World Organization for Animal Health (OIE), which 
is defined as freedom of rabies caused by RABV (OIE, 2013). 
The causative agent of terrestrial rabies is RABV and although all mammals are potentially 
susceptible to rabies, not all can serve as a reservoir for RABV. Next to the host species being 
highly susceptible, virus evolutionary factors, e.g. efficient and balanced replication and 
excretion and modification of host behaviour, as well as certain ecological factors, i.e. host 
density, social structure and population size must be met for independent transmission 
cycles to occur within a species (Mollentze et al., 2014).  
Known terrestrial reservoirs of RABV belong to the order Carnivora and include dogs (Canis 
lupus familiaris), red foxes (Vulpes vulpes), grey foxes (Urocyon cinereoargenteus), arctic 
foxes (Vulpes lagopus), bat-eared foxes (Otocyon megalotis), raccoon dogs (Nyctereutes 
procyonoides), raccoons (Procyon lotor), skunks (Mephitidae), Indian mongoose (Herpestes 
auropunctatus), jackals (Canis aureus, C. adustus, C. mesomelas) and Chinese ferret badgers 
(Melogale moschata) (WHO, 2013a). The most important reservoir for human infection is 
the dog, as 99% of human rabies cases are transmitted by rabid dogs (WHO, 2013a). 
Although elimination of dog rabies is feasible and was successful in Europe, Japan, parts of 
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Asia, North and most of South America, it still poses a problem in many parts of Asia and 
Africa (Coleman et al., 2004, WHO, 2013a). Asia has the highest rabies burden with India 
alone accounting for over 35 % of human rabies deaths (Hampson et al., 2015, Banyard et 
al., 2013). This is followed by Africa where ca. 36.4% of human rabies deaths occur. Asia and 
Africa also account for 95% of the estimated 3.7 million disability-adjusted life years, a 
measure for the years annually lost to rabies due to disease or premature death (Hampson 
et al., 2015). 
3.4.2. Bat rabies 
With ~1300 known species (Racey, 2015), bats (Chiroptera) are the second largest 
mammalian order after rodents (Burland and Wilmer, 2001). Bat speciation is performed 
either using morphological features or through phylogenetic analyses of host genes, though 
the first is challenging when dealing with cryptic species (Burland and Wilmer, 2001). With a 
quarter of all bat species threatened, many are protected, including all 53 bat species 
present in Europe (Racey, 2015, Lina, 2016, UNEP/EUROBATS, 1994). Although bats have 
certain characteristics which are presumed to make them special reservoirs for viruses, i.e. 
capability of flight, high roost densities, torpor and hibernation, long life spans and 
echolocation (Calisher et al., 2006), there is no clear indication that bats harbour a greater 
number of zoonotic viruses compared to other animal groups (Olival et al., 2015). 
Interestingly, the first virus discovered in bats was RABV and most lyssaviruses were found in 
bats or are known to have bats as their reservoir, which is why these animals are believed to 
be the ancestral hosts of all lyssaviruses (Banyard et al., 2011, Rupprecht et al., 2017). Within 
bats lyssaviruses display a restricted geographical distribution. This results in the conundrum 
that RABV is the only lyssavirus present in bats in the new world, while in the old world 
RABV has only been found in terrestrial mammals and other lyssavirus species are present in 
bats (Banyard et al., 2014a, Rupprecht et al., 2017). RABV is also responsible for most spill-
over infections of rabies from bats into terrestrial mammals and humans, and is the only 
lyssavirus where sustained spill-overs from bats into other mammals are known to have 
occurred (Badrane and Tordo, 2001, Kuzmin et al., 2012, Velasco-Villa et al., 2005, Daoust et 
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al., 1996, Leslie et al., 2006). Spill-over infections of other bat lyssaviruses are rare and have 
only been described sporadically (Johnson et al., 2010).  
3.4.2.1. Bat rabies in Europe 
Rabies is a notifiable disease in almost all European countries and monitored in the scope of 
surveillance programs, but less than half of these include bat rabies surveillance (Müller et 
al., 2016). Two forms of rabies surveillance exist: (i) Passive surveillance comprises the 
sampling of sick, rabies suspected or dead bats and bats which had contact to humans or 
domestic animals via bites or scratches. (ii) Active surveillance on the other hand describes 
the monitoring of lyssaviruses in free living bats, either through the detection of antibodies 
against lyssaviruses in serum samples or the detection of lyssavirus RNA or antigen in saliva 
samples (Med Vet Net Working Group, 2005). Despite great efforts, detection of virus RNA in 
oral swabs from European bats was rare and interpretation as well as comparison of 
serological results from different studies proves challenging due to cross neutralization of 
phlyogroup 1 lyssaviruses as well as the non-standardized serological test procedures 
(Freuling et al., 2009a, Schatz et al., 2014a). Thus, it was recommended to focus on passive 
bat rabies surveillance (Schatz et al., 2013b, Schatz et al., 2014a).  
A total of ca. 1123 bat rabies cases in Europe have been reported to the WHO Rabies Bulletin 
Europe in the scope of passive bat rabies surveillance between 1977 and 2015 (Anonymous, 
2017). In most cases EBLV-1 was identified as the causative agent (Schatz et al., 2013a). Two 
bat species serve as reservoir for this lyssavirus, i.e. the Serotine bat (Eptesicus serotinus) 
and the Isabelline serotine bat (Eptesicus isabellinus) (Vazquez-Moron et al., 2008, Montano-
Hirose et al., 1990). Furthermore, EBLV-1 can be divided into two genetic distinct 
sublineages. While EBLV-1a is present in an area between France, the Netherlands and 
Russia, EBLV-1b is present rather in western parts of Europe between Spain and Poland 
(Amengual et al., 1997, Davis et al., 2005). A third genetic sublineage comprising isolates 
from the Isabelline serotine bat from the Iberian Peninsula has been proposed (Vazquez-
Moron et al., 2011). Furthermore, additional variation in the genome, in the form of 
insertions and deletions (indels) in the UTRs of EBLV-1 isolates were found (Freuling et al., 
2012, Johnson et al., 2007). Single EBLV-1 infections of other bat species were recorded for 
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the common pipistrelle bat (Pipistrellus pipistrellus), the common noctule bat (Nyctalus 
noctula), the Nathusius' pipistrelle bat (Pipistrellus nathusii), the brown long-eared bat 
(Plecotus auritus) and the Barbastelle bat (Barbastella barbastellus) (Müller et al., 2007, 
Schatz et al., 2014a) as well as for a Natterer's bat (Myotis nattereri), a common bent-winged 
bat (Miniopterus schreibersii), a mouse-eared bat (Myotis myotis) and a greater horseshoed 
bat (Rhinolophus ferrumequinum) (Serra-Cobo et al., 2002). Additionally, EBLV-1 infections of 
Egyptian fruit bats (Rousettus agypticatus) in a colony from a Danish zoo have been reported 
(Rønsholt et al., 1998). Spill-over infections in terrestrial mammals, including two human 
rabies cases caused by EBLV-1, also occurred. These comprised EBLV-1 infections in sheep in 
Denmark, cats in France and a stone marten in Germany (Müller et al., 2004, Dacheux et al., 
2009, Tjornehoj et al., 2006). The first presumed spill-over of EBLV-1 to a human occurred in 
1977 in the Ukraine, where a small girl was bitten by a bat of unknown species (Fooks et al., 
2003a). The second human rabies case caused by EBLV-1 occurred in Russia in 1985, when a 
girl was bitten by a bat and died approximately one month later after developing rabies like 
symptoms (Selimov et al., 1989).  
The second lyssavirus present in Europe is EBLV-2 with 21 confirmed cases in bats until 2012 
(Schatz et al., 2013a). The majority of EBLV-2 cases were isolated from Daubenton's bats 
(Myotis daubentonii). In the Netherlands, EBLV-2 was isolated from five Pond bats (Myotis 
dasycneme), the only bat species from which EBLV-2 was isolated there (Schatz et al., 2013a, 
van der Poel et al., 2005). Two genetic lineages, EBLV-2a and EBLV-2b, exist for EBLV-2, 
although the phylogenetic support is weaker compared to EBLV-1. Due to limited data no 
correlation of the lineages with certain bat species can be established (Amengual et al., 
1997, McElhinney et al., 2013). Two human rabies cases caused by EBLV-2 have been 
recorded 1985 in Finland (Lumio et al., 1986) and 2002 in Scotland (Fooks et al., 2003b).  
Since the discovery of BBLV in 2010 in Germany, two additional cases were detected in 2012 
in Hemilly, France and Bavaria, Germany (Picard-Meyer et al., 2013, Freuling et al., 2013b, 
Freuling et al., 2011). All cases were found in Natterer's bats (Myotis nattereri), which is 
presumed to be the reservoir for BBLV (Banyard et al., 2014a).  
Single isolations of two additional lyssavirus species were detected in Common bent-winged 
bats (Miniopterus schreibersii) in Europe. WCBV was isolated in 2002 in the European 
Caucasus and LLEBV in 2012 in Spain (Botvinkin et al., 2003, Arechiga Ceballos et al., 2013, 
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Kuzmin et al., 2005). These lyssaviruses do not belong to phylogroup 1 (Banyard et al., 
2014a). 
3.4.2.2. Passive bat rabies surveillance in Germany 
In Germany passive bat rabies surveillance can be divided further into routine surveillance 
and enhanced passive bat rabies surveillance. Routine surveillance is performed by the 
regional veterinary laboratories of the sixteen federal states and was initiated in 1982 as 
beforehand bats were tested only sporadically for rabies (Müller et al., 2007). A presumed 
bat mediated human rabies case in Denmark further sparked surveillance efforts, as before 
bat rabies surveillance was only thought to be of interest for scientific reasons (Seidler et al., 
1987). In the scope of routine surveillance only bats with symptoms suggestive of rabies or 
where human contact in form of bites and scratches has occurred are examined (Müller et 
al., 2007). Approximately 2076 bats were tested for bat rabies during routine surveillance 
until 2015 (Anonymous) with 272 detected rabies cases (Anonymous, 2017). The majority of 
cases were caused by EBLV-1, but one case of EBLV-2 as well as the first case of BBLV in 2010 
were also detected during routine surveillance (Schatz et al., 2014a).  
In 1998, an additional enhanced passive bat rabies surveillance study was initiated, where 
dead found bats from bat collections, not suspected of rabies, were included (Schatz et al., 
2014a). Until June 2013 a total of 5478 bats were investigated, with the most frequently 
submitted bat species being the common pipistrelle bat and the common noctule bat. Fifty-
six bat rabies cases were found during enhanced passive bat rabies surveillance, and in 52 
cases EBLV-1 and in three cases EBLV-2 were identified as the causative agents (Schatz et al, 
2014). The resulting prevalence of bat rabies during enhanced passive bat rabies surveillance 
was much lower compared to routine surveillance and more likely represents the true 
prevalence of bat rabies in Germany (Schatz et al, 2014). 
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Figure 2: Surveillance efforts and geographical distribution of reported bat rabies cases in 
Germany until 2014. A) Bats sampled during routine surveillance which tested negative (blue 
dots) and positive (red dots) for bat rabies. B) Bats sampled during enhanced passive 
surveillance which tested negative (blue dots) and positive (red dots) for bat rabies. A) + B) 
Red and green circles mark cases of EBLV-2 and BBLV respectively. C) Bat rabies cases caused 
by EBLV-1a (red dots) and EBLV-1b (blue dots). D) Bat rabies cases caused by EBLV-2 (red 
dots) and BBLV (stars). (© Friedrich-Loeffler-Institut Insel Riems) 
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3.5. Rabies diagnosis 
Rabies diagnosis in animals is preferably made post mortem from brain material and ideally 
different brain regions, i.e. brain stem, Ammon´s horn, cortex, cerebellum and thalamus, are 
tested (Müller, 2017, OIE, 2012). Ante mortem diagnosis should only be performed in human 
suspect rabies cases, and comprises the testing of preferentially saliva and head skin 
biopsies at different time points (Crepin et al., 1998, WHO, 2013a). Since virus shedding in 
saliva is intermittent and skin biopsies not always positive, these tests can only confirm but 
not exclude rabies (WHO, 2013a). Due to late seroconversion, serology is rarely used for 
ante-mortem diagnosis but mostly for epidemiological studies and the assessment of 
seroconversion following vaccination (OIE, 2012). 
3.5.1. Standard diagnostic tests 
The gold standard for rabies diagnosis is the fluorescence antibody test (FAT), due to 
accuracy and speed, which is recommended by the WHO and OIE (OIE, 2012). Virus antigen 
is detected in brain smears fixed on slides, by staining them with fluorophore-conjugated 
(FITC) anti-rabies antibodies. The slides are evaluated under a fluorescence microscope, 
which emits ultraviolet light, causing the fluorophore to emit a light signal. This can be seen 
as green fluorescence (Dean et al., 1996, Goldwasser and Kissling, 1958). If the FAT result is 
inconclusive or in cases of human exposure further tests are recommended (OIE, 2012). The 
rabies tissue culture infection test (RTCIT) has replaced the mouse inoculation test (MIT), 
which is no longer recommended due to ethical reasons (Müller et al., 2016). In the RTCIT 
virus is isolated in mouse neuroblastoma cell culture from brain suspensions, thus only 
viable virus can be detected (Webster and Casey, 1996, Rudd and Trimarchi, 1989). Although 
not yet recommended by the WHO as a diagnostic test, reverse transcription polymerase 
chain reaction (RT-PCR) is increasingly used in rabies diagnosis, e.g. for the verification of 
FAT results (Müller, 2017, WHO, 2013a, Dacheux et al., 2010, Fooks et al., 2009). Next to a 
high sensitivity, RT-PCR has the additional advantage that identification of the lyssavirus 
species in the scope of multiplex RT-PCR or sequencing of PCR products is possible 
(Woldehiwet, 2005). 
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3.5.2. Challenges in rabies diagnosis 
Sample acquisition and transport to the laboratory are the first steps for diagnosing rabies 
and already pose difficulties. To obtain brain samples, the skull needs to be opened, which 
should be performed by well-trained technicians, with precautionary measures taken to 
avoid accidental exposure or cross contamination. To circumvent these challenges, 
alternative sampling methods were developed where brain material is obtained by insertion 
of a straw or syringe either via the occipital foramen or following trepanation of the eye 
socket (Montano-Hirose et al., 1991, Barrat and Halek, 1986). Immediately after removal, 
sample material should ideally be frozen and in this condition transported to a laboratory 
(OIE, 2012). In order to preserve sample material for testing without freezing, storage in 
Formalin or 50% Glycerol is possible, although these preservation techniques present some 
disadvantages. Since Formalin inactivates the virus, virus isolation is no longer possible and 
FAT as well as PCR display decreased sensitivity. Although Glycerol does not inactivate the 
virus, it only protects the sample from putrefaction and virus inactivation due to high 
temperatures still occurs and it is recommended by the OIE to store Glycerol samples in a 
refrigerator (OIE, 2012, Barrat, 1996). The implementation of standard diagnostic tests for 
rabies is also challenging for developing countries. The FAT for example needs expensive 
FITC anti-rabies antibodies and a fluorescence microscope for evaluation. Furthermore, 
evaluation should only be performed by trained staff (Duong et al., 2016, Woldehiwet, 2005, 
Banyard et al., 2013). Similar to FAT, RTCIT also requires a fluorescence microscope and 
trained staff, as well as an established cell culture system and adequate biosafety (Duong et 
al., 2016, Webster and Casey, 1996). Expensive equipment is also needed for RT-PCR and 
without appropriate standardization and quality control false positive as well as false 
negative results can occur (Duong et al., 2016, OIE, 2012, Notomi et al., 2000). 
These problems are especially apparent in developing countries in Asia and Africa, where 
dog rabies still poses a major human health threat (Fooks et al., 2009, Banyard et al., 2013). 
Coupled with lack of awareness of the general public, weak capacity for field investigation of 
rabies cases, poor infrastructure, poor veterinary and health capacity as well as their 
insufficient cooperation, and inadequate reporting systems, the result is inadequate rabies 
surveillance (Townsend et al., 2013, Banyard et al., 2013). In fact, insufficient surveillance 
leads to an underestimation of the situation, therefore attracting little attention from policy 
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makers, resulting in a cycle of neglect (Cleaveland et al., 2014). Furthermore, surveillance is 
crucial for canine rabies elimination programs, since it provides data on the progress and 
cost effectiveness, enabling sustainable implementation (Townsend et al., 2013). 
3.5.3. Alternative diagnostic tests 
To overcome some of the challenges in rabies diagnosis, alternative test methods have been 
developed. The direct rapid immunohistochemical test (dRIT) was developed by the Centers 
for Disease Control and Prevention (CDC) as an alternative to FAT (Lembo et al., 2006). In 
dRIT rabies antigen is detected with biotinylated anti-N antibodies. Biotin catalyses the 
formation of a red precipitate which can be observed using a conventional light microscope 
(Coetzer et al., 2014a). The evaluation of the test with a light microscope is the biggest 
advantage of dRIT compared to FAT. Other advantages are easier interpretation of test 
results and reduced costs compared to FAT (Fooks et al., 2009, Coetzer et al., 2014a). The 
dRIT was evaluated in several studies and showed sensitivities between 83% and 100% 
depending on the antibodies used and was able to detect other lyssaviruses apart from 
RABV, i.e. MOKV, LBV and DUVV (Coetzer et al., 2014a, Coetzer et al., 2014b, Lembo et al., 
2006, Madhusudana et al., 2012). 
Novel approaches for the rapid amplification and detection of lyssavirus RNA are reverse 
transcription loop mediated isothermal amplification (RT-LAMP) and nucleic acid sequence 
based amplification (NASBA), where amplification occurs at a constant temperature, 
eliminating the need for a high precision thermal cycler (Notomi et al., 2000, Compton, 
1991). NASBA allows direct isothermal amplification of RNA (Compton, 1991). Gene 
amplification occurs at a relatively low temperature of 40°C, which is advantageous for the 
in situ detection of viral RNA, due to less cell damage compared to RT-PCR (Sugiyama et al., 
2003). RNA amplification requires three enzymes, which are the T7 RNA polymerase, the 
avian myeloblastosis virus reverse transcriptase and RNase H (Guatelli et al., 1990). Two 
studies assessed NASBA techniques for the detection of RABV RNA, with mixed results 
(Wacharapluesadee et al., 2011, Wacharapluesadee and Hemachudha, 2001). In rabies 
diagnosis, NASBA was used for the ante mortem diagnosis of rabies in humans 
(Wacharapluesadee and Hemachudha, 2010). Isothermal amplification of deoxyribonucleic 
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acid (DNA) during RT-LAMP requires a higher temperature of 65°C compared to NASBA. As, 
similar to RT-PCR, direct amplification of virus RNA with LAMP is not possible, a reverse 
transcription step has to be included. RT-LAMP displays very high specificities, which can 
have a negative effect on the sensitivities of the assays (Ito et al., 2014). Indeed two RT-
LAMP assays developed for rabies diagnosis displayed reduced sensitivity due to sequence 
variation of the RABV isolates (Saitou et al., 2010, Boldbaatar et al., 2009). For the 
development of a RT-LAMP assay to detect RABV isolates of two African lineages, two primer 
sets, 12 primers in total, were needed (Hayman et al., 2011). Therefore, the development of 
a RT-LAMP able to detect a broad spectrum of RABV isolates is challenging. 
Another test, developed as a point of care test for the detection of antigen is the lateral flow 
device (LFD), also called lateral flow assay, rapid immunodiagnostic test or rapid 
immunochromatographic strip test (O’Farrell, 2013, Kang et al., 2007, Mak et al., 2016) . The 
test principle is based on fluid migration along a membrane. A sample is added to the 
sample area of a test strip from where it migrates along the strip, the antigen in the sample 
reacting with conjugated and fixed antibodies, resulting in the development of lines visible 
to the naked eye (O’Farrell, 2013). Since the test allows a one-step analysis, it is easy to 
perform. Furthermore, the test can be stored at room temperature and does not need any 
additional equipment and chemicals. Therefore, it has potential for field use. Coupled with 
being rapid and cost effective it is applied in many areas, e.g. environmental science, human 
and animal health (Ngom et al., 2010, Posthuma-Trumpie et al., 2009). LFDs require small 
sample volumes. These result subsequently in small quantities of analyte, which can lower 
the sensitivity of the test. On the other hand, small sample volumes can be advantageous, 
when not much material is available, as long as sensitivities are adequate. Due to test 
components and manufacturing processes the tests can display variable sensitivity and test 
reproducibility (O’Farrell, 2013). For rabies diagnosis one commercially available LFD, 
produced by Bionote, has been evaluated in several studies reporting sensitivities between 
88% and 100% (Table 3). 
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Table 3: Summary of studies evaluating Bionote LFD and respective results.             
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4.Objectives 
Assessment of EBLV-1 pathogenicity: 
Five lyssavirus species circulate in Europe, with EBLV-1 being responsible for most bat rabies 
cases, including spill-over infections in other mammals including humans. The pathogenicity 
of EBLV-1 has so far only been assessed in studies using single isolates as representatives. 
Since these studies were all designed differently no comparison can be made between the 
different isolates used. As there are genetic differences between EBLV-1 isolates and it is 
known for other lyssaviruses that genetic variation can influence the pathogenicity, one aim 
of this thesis was to assess the pathogenic properties of EBLV-1 isolates with genetic 
differences using the same experimental design. 
Enhanced passive bat rabies surveillance in Germany: 
In Germany three bat lyssavirus species have been detected, which present a human health 
threat. To better understand the epidemiology and dynamics of bat rabies in Germany, 
enhanced passive bat rabies surveillance was performed until 2014. This surveillance was 
continued to keep up to date with the situation also with respect of the discovery of novel 
lyssaviruses in Germany in 2010 and Spain in 2013.  
LFDs as a tool for rabies surveillance in developing countries: 
Terrestrial rabies caused by RABV, especially dog-mediated rabies, is responsible for most 
human rabies cases. Dog-mediated human rabies is still prevalent in many regions but 
foremost in developing countries in Asia and Africa. To establish efficient rabies control 
measures, adequate rabies surveillance is required, which is difficult due to the nature of 
standard diagnostic tests for rabies. To circumvent this problem other test methods were 
developed, including LFDs. So far only one commercially available LFD has been evaluated, 
although several products are on the market, without anything known regarding their 
performance. Therefore, the performance of several commercially available LFDs was 
assessed. 
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5.Results 
 
5.1. Comparative analysis of European bat lyssavirus 1 isolates in the mouse 
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The manuscript is presented in its published form and has therefore its own reference 
section. References and abbreviations from the manuscript are not included in the relevant 
sections at the beginning and the end of this document. The corresponding supplement 
material has been added directly following the reference section of this publication. 
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Supplementary Table 1: Clinical score sheet of the mice, ranging from zero up to four. 
Score Symptoms 
0  healthy
1 
 ruffled fur
 hunched back
 hypermetria in inoculated limb
 wobbly gait in inoculated limb
 calm
2 
 ruffled fur
 hunched back
 slow movements
 wobbly gait both hind limbs
 jumpy
 tame
3 
 paralysis or spasms in hind limbs
 agressiveness
 biting of objects and other mice
 automutilation
 circular movements
4  death
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Supplementary Figure 1: a) two step and b) one step replication kinetics of the isolates 
used in the study. 
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Supplementary Figure 2: Survival curves of the mice following i.c. inoculation. 
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Supplementary Figure 3: Percentage seroconversion for the different inoculation routes 
following inoculation a) with EBLV-1 isolates and b) with RABV isolates. Percentage of 
seroconverted mice for the individual isolates can be seen following i.m. inoculation with 
c) high doses and d) low doses. 
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Supplementary Table 2: The 28 potentially significant amino acid exchanges in the proteins 
of the EBLV-1 isolates and their frequency in other EBLV-1 as well as in RABV isolates. 
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Supplementary Table 3: Summary of known pathogenicity determining sites and the 
protein sequences found in the RABV as well as in the EBLV-1 isolates used in this study. 
 R
ef
er
en
ce
(M
as
at
an
i, 
It
o
 e
t 
al
. 
2
0
1
1
)
(K
ga
la
d
i, 
W
ri
gh
t 
et
 a
l. 
2
0
1
3
)
(K
ga
la
d
i, 
W
ri
gh
t 
et
 a
l. 
2
0
1
3
)
(R
ie
d
er
, 
B
rz
o
zk
a 
et
 a
l. 
2
0
1
1
)
(B
rz
o
zk
a,
 F
in
k
e 
et
 a
l. 
2
0
0
6
)
(W
ir
b
lic
h,
 T
an
 e
t 
al
. 
2
0
0
8
)
(K
ga
la
d
i, 
W
ri
gh
t 
et
 a
l. 
2
0
1
3
)
(G
ho
la
m
i, 
K
as
si
s 
et
 a
l. 
2
0
0
8
)
(M
ita
, 
S
hi
m
iz
u 
et
 
al
. 
2
0
0
8
)
p
o
si
tio
n
A
A
2
7
3
A
A
3
9
4
A
A
 1
4
4
-1
4
8
A
A
1
7
6
-1
8
6
A
A
2
8
9
-2
9
8
A
A
3
5
-3
8
A
A
7
7
A
A
8
1
A
A
9
5
1
3
4
5
4
_
E
B
L
V
-1
a_
re
f
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
5
7
8
2
_
E
B
L
V
-1
a_
d
el
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
5
7
7
6
_
E
B
L
V
-1
a_
in
s
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
9
7
6
_
E
B
L
V
-1
a_
d
is
t
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
1
3
0
2
7
_
E
B
L
V
-1
a_
Y
ul
i
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
2
0
1
7
4
_
E
B
L
V
-1
b
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
5
0
0
6
_
E
B
L
V
-1
b
_
in
s
F
F
K
S
T
Q
T
P
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
1
3
4
2
4
_
E
B
L
V
-1
c
F
F
K
S
T
Q
T
S
Q
E
S
S
G
P
P
G
L
D
Q
D
D
L
N
R
Y
L
A
Y
P
P
E
Y
S
G
V
3
5
0
0
9
_
R
A
B
V
_
C
V
S
F
Y
K
S
T
Q
T
A
Q
V
A
P
G
P
P
A
L
E
Q
D
D
L
N
R
Y
T
S
C
P
P
E
Y
R
E
V
5
9
8
9
_
R
A
B
V
_
d
o
g_
az
er
b
F
Y
K
S
T
Q
T
A
Q
A
A
S
G
P
P
A
L
E
Q
D
D
L
N
R
Y
A
S
C
P
P
E
Y
R
E
V
N
uc
le
o
p
ro
te
in
P
ho
sp
ho
p
ro
te
in
M
at
ri
xp
ro
te
in
Results 
 
 
60 
 R
ef
er
en
ce
(F
ab
er
, 
F
ab
er
 
et
 a
l. 
2
0
0
5
)
(L
en
tz
, 
W
ils
o
n 
et
 a
l. 
1
9
8
4
)
(T
ak
ay
am
a-
It
o
, 
It
o
 
et
 a
l. 
2
0
0
6
)
(K
ga
la
d
i, 
W
ri
gh
t 
et
 
al
. 
2
0
1
3
)
(K
ga
la
d
i, 
W
ri
gh
t 
et
 a
l. 
2
0
1
3
)
(L
an
ge
vi
n 
an
d
 
T
uf
fe
re
au
 2
0
0
2
)
(K
ga
la
d
i, 
W
ri
gh
t 
et
 
al
. 
2
0
1
3
)
(T
uf
fe
re
au
, 
L
eb
lo
is
 e
t 
al
. 
1
9
8
9
)
(P
re
ha
ud
, 
W
o
lff
 e
t 
al
. 
2
0
1
0
)
p
o
si
tio
n
A
A
 1
9
4
A
A
1
9
8
A
A
2
4
2
A
A
2
5
5
A
A
2
6
8
A
A
3
1
8
A
A
3
5
2
A
A
3
3
0
-3
3
3
A
A
5
0
2
-5
0
6
1
3
4
5
4
_
E
B
L
V
-1
a_
re
f
T
K
S
D
I
I
H
K
S
V
R
T
G
E
S
5
7
8
2
_
E
B
L
V
-1
a_
d
el
T
K
S
D
I
I
H
K
S
V
R
T
G
E
S
5
7
7
6
_
E
B
L
V
-1
a_
in
s
T
K
S
D
I
I
H
K
S
V
R
T
G
E
S
9
7
6
_
E
B
L
V
-1
a_
d
is
t
T
K
S
D
I
I
H
K
S
V
R
T
G
E
S
1
3
0
2
7
_
E
B
L
V
-1
a_
Y
ul
i
T
K
S
D
I
I
H
K
S
V
R
T
G
E
S
2
0
1
7
4
_
E
B
L
V
-1
b
T
K
S
D
I
I
H
K
S
V
R
T
S
E
S
5
0
0
6
_
E
B
L
V
-1
b
_
in
s
T
K
S
D
I
I
H
K
S
V
R
T
S
E
S
1
3
4
2
4
_
E
B
L
V
-1
c
T
K
S
D
I
I
H
K
S
V
R
T
S
E
S
3
5
0
0
9
_
R
A
B
V
_
C
V
S
N
K
A
D
I
F
H
K
S
V
R
E
IR
L
5
9
8
9
_
R
A
B
V
_
d
o
g_
az
er
b
N
K
A
D
I
F
H
K
S
V
R
E
T
R
L
G
ly
co
p
ro
te
in
Results 
 
 
61 
 
 
References for S3 Table: 
Brzozka, K., S. Finke and K. K. Conzelmann (2006). "Inhibition of interferon signaling by rabies virus 
phosphoprotein P: activation-dependent binding of STAT1 and STAT2." J Virol 80(6): 2675-2683. 
Faber, M., M. L. Faber, A. Papaneri, M. Bette, E. Weihe, B. Dietzschold and M. J. Schnell (2005). "A Single Amino 
Acid Change in Rabies Virus Glycoprotein Increases Virus Spread and Enhances Virus Pathogenicity." Journal of 
Virology 79(22): 14141-14148. 
Gholami, A., R. Kassis, E. Real, O. Delmas, S. Guadagnini, F. Larrous, D. Obach, M. C. Prevost, Y. Jacob and H. 
Bourhy (2008). "Mitochondrial dysfunction in lyssavirus-induced apoptosis." Journal of Virology 82(10): 4774-
4784. 
Kgaladi, J., N. Wright, J. Coertse, W. Markotter, D. Marston, A. R. Fooks, C. M. Freuling, T. F. Müller, C. T. Sabeta 
and L. H. Nel (2013). "Diversity and Epidemiology of Mokola Virus." PLoS Negl Trop Dis 7(10): e2511. 
Langevin, C. and C. Tuffereau (2002). "Mutations conferring resistance to neutralization by a soluble form of 
the neurotrophin receptor (p75NTR) map outside of the known antigenic sites of the rabies virus glycoprotein." 
J Virol 76(21): 10756-10765. 
Lentz, T. L., P. T. Wilson, E. Hawrot and D. W. Speicher (1984). "Amino acid sequence similarity between rabies 
virus glycoprotein and snake venom curaremimetic neurotoxins." Science 226(4676): 847-848. 
Masatani, T., N. Ito, K. Shimizu, Y. Ito, K. Nakagawa, M. Abe, S. Yamaoka and M. Sugiyama (2011). "Amino acids 
at positions 273 and 394 in rabies virus nucleoprotein are important for both evasion of host RIG-I-mediated 
antiviral response and pathogenicity." Virus Res 155(1): 168-174. 
Mita, T., K. Shimizu, N. Ito, K. Yamada, Y. Ito, M. Sugiyama and N. Minamoto (2008). "Amino acid at position 95 
of the matrix protein is a cytopathic determinant of rabies virus." Virus Research 137(1): 33-39. 
Prehaud, C., N. Wolff, E. Terrien, M. Lafage, F. Megret, N. Babault, F. Cordier, G. S. Tan, E. Maitrepierre, P. 
Menager, D. Chopy, S. Hoos, P. England, M. Delepierre, M. J. Schnell, H. Buc and M. Lafon (2010). "Attenuation 
of rabies virulence: takeover by the cytoplasmic domain of its envelope protein." Sci Signal 3(105): ra5. 
R
ef
er
en
ce
p
o
si
tio
n
A
A
1
6
8
5
A
A
1
7
9
7
A
A
1
8
2
9
A
A
1
8
6
7
1
3
4
5
4
_
E
B
L
V
-1
a_
re
f
K
D
K
E
5
7
8
2
_
E
B
L
V
-1
a_
d
el
K
D
K
E
5
7
7
6
_
E
B
L
V
-1
a_
in
s
K
D
K
E
9
7
6
_
E
B
L
V
-1
a_
d
is
t
K
D
K
E
1
3
0
2
7
_
E
B
L
V
-1
a_
Y
ul
i
K
D
K
E
2
0
1
7
4
_
E
B
L
V
-1
b
K
D
K
E
5
0
0
6
_
E
B
L
V
-1
b
_
in
s
K
D
K
E
1
3
4
2
4
_
E
B
L
V
-1
c
K
D
K
E
3
5
0
0
9
_
R
A
B
V
_
C
V
S
K
D
K
E
5
9
8
9
_
R
A
B
V
_
d
o
g_
az
er
b
K
D
K
E
(T
ia
n,
 L
uo
 e
t 
al
. 
2
0
1
5
)
L
ar
ge
 p
ro
te
in
Results 
 
 
62 
Rieder, M., K. Brzozka, C. K. Pfaller, J. H. Cox, L. Stitz and K. K. Conzelmann (2011). "Genetic dissection of 
interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 
activation is important for pathogenicity." J Virol 85(2): 842-852. 
Takayama-Ito, M., N. Ito, K. Yamada, M. Sugiyama and N. Minamoto (2006). "Multiple amino acids in the 
glycoprotein of rabies virus are responsible for pathogenicity in adult mice." Virus Res. 115(2): 169-175. 
Tian, D., Z. Luo, M. Zhou, M. Li, L. Yu, C. Wang, J. Yuan, F. Li, B. Tian, B. Sui, H. Chen, Z. F. Fu and L. Zhao (2015). 
"Critical Role of K1685 and K1829 in the Large Protein of Rabies Virus in Viral Pathogenicity and Immune 
Evasion." J Virol 90(1): 232-244. 
Tuffereau, C., H. Leblois, J. Benejean, P. Coulon, F. Lafay and A. Flamand (1989). "Arginine or lysine in position 
333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice." Virology 172(1): 206-212. 
Wirblich, C., G. S. Tan, A. Papaneri, P. J. Godlewski, J. M. Orenstein, R. N. Harty and M. J. Schnell (2008). "PPEY 
motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity." J 
Virol 82(19): 9730-9738. 
 
  
Results 
 
 
63 
Supplementary Table 4: Summary of previous pathogenicity studies with EBLV-1 as well as 
details to their experimental design. 13454* is identical to 13454_EBLV-1a_ref used in this 
study. 
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The manuscript is presented in the form accepted for publication and has its own content 
and reference sections. References and abbreviations from the manuscript are not included 
in the relevant sections at the beginning and the end of this document. 
Figures and tables are numbered individually within the manuscript and correspond to the 
published form. 
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Abstract 
In 2010, a novel lyssavirus named Bokeloh bat lyssavirus (BBLV) was isolated from a 
Natterer’s bat (Myotis nattereri) in Germany. Two further viruses were isolated in the same 
country and in France in recent years, all from the same bat species and all found in 
moribund or dead bats. Here we report the description and the full-length genome sequence 
of five additional BBLV isolates from Germany (n=4) and France (n=1). Interestingly, all of 
them were isolated from the Natterer’s bat, except one from Germany, which was found in a 
common Pipistrelle bat (Pipistrellus pipistrellus), a widespread and abundant bat species in 
Europe. The latter represents the first case of transmission of BBLV to another bat species. 
Phylogenetic analysis clearly demonstrated the presence of two different lineages among 
this lyssavirus species: lineages A and B. The spatial distribution of these two lineages 
remains puzzling, as both of them comprised isolates from France and Germany; although 
clustering of isolates was observed on a regional scale, especially in Germany. Phylogenetic 
analysis based on the mitochondrial cytochrome b (CYTB) gene from positive Natterer’s bat 
did not suggest a circulation of the respective BBLV sublineages in specific Natterer’s bat 
subspecies, as all of them were shown to belong to the Myotis nattereri sensu stricto 
clade/subspecies and were closely related (German and French positive bats). At the bat 
host level, we demonstrated that the distribution of BBLV at the late stage of the disease 
seems large and massive, as viral RNA was detected in many different organs.  
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1. Introduction 
1.1. Rabies and bats 
Rabies is an acute, progressive incurable viral encephalitis that is transmitted following bites 
or scratches by infected mammals. Whilst the name rabies is derived from the Latin name 
for ‘madness’, the old Greeks derived the word lyssa, from lud or "violent"; this root is used 
in the name of the genus Lyssavirus (Jackson, 2013). Lyssaviruses, the causative agents of 
rabies, are negative single strand RNA viruses of the Rhabdoviridae family, and alongside 
with the Bornaviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, Mymonaviridae, 
Nyamiviridae and Sunviridae forms the order Mononegavirales (Afonso et al., 2016). They 
are currently classified into 14 officially recognized (ICTV, 2015) and two yet unassigned 
species (Arechiga Ceballos et al., 2013; Gunawardena et al., 2016). All lyssaviruses appear or 
are suspected to follow a rabies like pathogenesis (Davis et al., 2015). With the advent of 
novel molecular techniques, the Rhabdoviridae family was extended (Dietzgen et al., 2017). 
In this chapter we summarize the current situation in the genus Lyssavirus and with Bokeloh 
bat lyssavirus (BBLV) provide a recent example how the genus diversifies.  
While rabies caused by the archetypical rabies virus (RABV, belonging to Rabies lyssavirus 
species) has been known for millennia (Jackson, 2013), causing tens of thousands of human 
deaths per year (Hampson et al., 2015), the association of rabies with bats (Chiroptera) was 
first demonstrated in the New World in the early 20th Century (Pawan, 1936). Since the 
appearance of first descriptions of RABV in bats in the Americas, other divergent lyssavirus 
species have been detected in a wide range of chiropteran hosts, and bats are the 
recognized reservoirs for the majority of lyssaviruses (Banyard et al., 2013). Furthermore, 
there is strong ecological as well as phylogenetic support that bat derived viruses have 
evolved long before those RABV of terrestrial carnivore origin (Badrane and Tordo, 2001; 
Troupin et al., 2016). However, the evolutionary history of lyssaviruses within bats is 
unresolved. For instance, the absence of non-RABV lyssaviruses in bats in the Americas, and 
the diversity of bat lyssaviruses elsewhere in the Old World remain enigmatic and may 
indicate an ancient co-evolution and dispersal of lyssaviruses and their reservoir hosts, i.e. 
primarily bats (Rupprecht et al., 2017). 
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1.2. Bat rabies in the Americas 
Rabies in bats in the Americas is in some aspects different to the Old World. As introduced 
before, the sole causative agents are exclusively variants of classical RABV. However, rabies 
virus is found in many species of bat in the Americas (Banyard et al., 2013; Constantine, 
2009; Sodre et al., 2010), and it was demonstrated that particular bat species are associated 
with specific RABV variants (Hughes et al., 2005; Streicker et al., 2010; Velasco-Villa et al., 
2006). Among bats, cross-species transmissions (CSTs) seem to be related to the relative 
genetic distance of the host (Streicker et al., 2010). Also, bat RABV variants caused a 
historical sustained CST in raccoons (Velasco-Villa et al., 2008), and more recent CST in 
striped skunks (Mephitis mephitis), red foxes (Vulpes vulpes) and gray foxes (Urocyon 
cinereoargenteus) (Daoust et al., 1996; Kuzmin et al., 2012; Leslie et al., 2006). A bat rabies 
variant was also responsible for rabies cases in white-nosed coati (Nasua narica) (Arechiga-
Ceballos et al., 2010).  
In Latin America, besides insectivorous and frugivorous bat species, the common vampire 
bat (Desmodus rotundus), one of three blood-feeding or hematophagous bats found 
exclusively in this region, acts as a reservoir for rabies (Johnson et al., 2014). This behaviour 
facilitates virus transmission not only to livestock, particularly cattle (Arellano-Sota, 1988; 
Johnson et al., 2014), but also causes human cases, particularly in remote areas with limited 
access to medical intervention (Condori-Condori et al., 2013; Meynard et al., 2012; Stoner-
Duncan et al., 2014; Streicker et al., 2012). 
1.3. Bat rabies in Asia and Australia 
Rabies in bats in the Asian part of Russia were described already in the 1970s. However, 
tracing back of these early isolates could not confirm the presence of bat associated 
lyssaviruses (Kuzmin et al., 2006a). The first well documented and verified isolation of a 
lyssavirus from a bat occurred in 1991, when a novel lyssavirus, named Aravan virus (ARAV) 
was isolated from a lesser mouse-eared bat (Myotis blythii) in Kyrghyzstan. The discovery of 
Khujand virus (KHUV) in a whiskered bat (Myotis mystacinus) followed in 2001 (Kuzmin et al., 
2003). One year later another novel lyssavirus virus, Irkut virus (IRKV) was discovered in the 
Irkutsk province of Russia, when a bat caught indoors died approximately 10 days later after 
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developing clinical signs (Botvinkin et al., 2003). IRKV is insofar distinctive from the other 
Asian lyssaviruses as further cases were reported in China in a greater tubenosed bat 
(Murina leucogaster) (Liu et al., 2013), as well as a human rabies case in 2007 in the Russian 
Far East (Leonova et al., 2009). Most recently, Gannoruwa bat lyssavirus (GBLV) was isolated 
from Indian flying foxes (Pteropus medius) in Sri Lanka, after 62 grounded and dead found 
bats were tested for the presence of lyssaviruses (Gunawardena et al., 2016). Further 
surveillance and search for bat pathogens including lyssaviruses will likely expand the 
diversity and range of bat-associated lyssaviruses in Asia. In fact, serological surveys of bats 
indicate the presence of lyssaviruses in several countries in Southeast Asia, i.e. the 
Philippines (Arguin et al., 2002), Cambodia (Reynes et al., 2004), Thailand (Lumlertdacha et 
al., 2005), Bangladesh (Kuzmin et al., 2006b), China (Jiang et al., 2010) and Vietnam (Nguyen 
et al., 2014).  
Australian bat lyssavirus (ABLV) was initially discovered in the brain of a black flying fox 
(Pteropus alecto) and is predominantly associated with fruit eating bat species (Fraser et al., 
1996; Weir et al., 2014). Interestingly, ABLV infection has only been confirmed by virus 
isolation in one insectivorous species, the yellow-bellied sheath-tailed bat (Saccolaimus 
flaviventris). Genetically, ABLV is also delineated into two lineages associated with either 
fruit bats or insectivorous bats, respectively (Barrat, 2004). ABLV infection caused three 
known human cases in Queensland, Australia (Johnson et al., 2010), and spill-over infections 
were identified in two horses with neurological disease (Annand and Reid, 2014). 
1.4. Bat rabies in Africa 
Of note, the first indication of the circulation of lyssaviruses other than RABV was 
demonstrated by early virological investigations in Africa (Boulger and Porterfield, 1958; 
Shope et al., 1970), and the virus isolated from a straw-coloured fruit bat (Eidolon helvum) in 
Nigeria in 1956 was named Lagos bat virus (LBV). LBV infections were reported from several 
African countries, including detections in other bat species, dogs, cats and one water 
mongoose (Markotter et al., 2006; Sabeta et al., 2007). Analysis of the virus phylogeny 
suggests the existence of four major LBV genetic lineages. The genetic distances between 
some lineages is greater than those established as a demarcation criterion for individual 
lyssavirus species (Markotter et al., 2008). Serosurveys revealed a high seroprevalence of 
antibodies against LBV, and thus indicated the circulation of LBV in various fruit bat species 
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across parts of Africa (Dzikwi et al., 2010; Freuling et al., 2015; Hayman et al., 2008; Hayman 
et al., 2012; Kalemba et al., 2017; Kuzmin et al., 2008a). 
Closely related to LBV is Shimoni bat virus (SHIBV), which was isolated from a dead 
Commerson’s leaf-nosed bat (Hipposideros commersoni) during a search for bat associated 
pathogens in Kenya (Kuzmin et al., 2010). Comparative serological surveys in Rousettus 
aegyptiacus bats and Hipposideros commersoni bats in sympatric roosts in Kenya suggested 
that H. commersoni is a primary host species of SHIBV (Kuzmin et al., 2011). 
Duvenhage virus (DUVV) was isolated in 1970 in South Africa following the death of a human 
that was bitten by an insectivorous bat (Meredith et al., 1971). Sporadically, DUVV was 
reported from insectivorous bats in Southern Africa (Paweska et al., 2006; Weyer et al., 
2011) and caused two additional fatal human infections in South Africa (Paweska et al., 
2006) and in the Netherlands (following a contamination in Kenya)(Van Thiel et al., 2008). 
1.5. Bat rabies in Europe 
In Europe, the first rabid bat was diagnosed in 1954 in Germany (Mohr, 1957). Other and 
only sporadic reports indicated the presence of bat associated rabies in Europe until the 
1980s (Müller et al., 2007), when two human rabies cases due to bat contact sparked 
surveillance efforts in many European countries (Johnson et al., 2010). From 1977 until 2016, 
bat rabies was confirmed in 1180 cases during bat rabies surveillance activities across 
Europe (Source: Rabies Bulletin Europe database, found at: http://www.who-rabies-
bulletin.org/ accessed May 2017). A recent study evaluating all available data on bat rabies 
surveillance across Europe concluded that bat rabies surveillance is not evenly conducted 
(Schatz et al., 2013). Therefore, while cases detected in bats indicate the circulation among 
bats in that region, the absence of evidence is not the evidence of absence.  
Molecular characterization initially demonstrated that viruses isolated from European bats 
and human cases belong to two genetically diverse lyssaviruses, European bat lyssavirus type 
1 (EBLV-1) and European bat lyssavirus type 2 (EBLV-2), belonging to European bat 1 
lyssavirus and European bat 2 lyssavirus species, respectively (Amengual et al., 1997; Bourhy 
et al., 1993; Davis et al., 2005). While serotine bats (Eptesicus serotinus and E. isabellinus) 
are considered the primary reservoir hosts for EBLV-1, rabies cases in Daubenton’s bats 
(Myotis daubentonii) and pond bats (Myotis dasycneme) were genetically characterized as 
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EBLV-2 (Banyard et al., 2013). Besides the European bat lyssaviruses, two other unrelated 
bat lyssaviruses were also isolated from common bent-winged bats (Miniopterus 
schreibersii) in the Caucasus region (West Caucasian bat lyssavirus –WCBV- belonging to 
West Caucasian bat lyssavirus species, (Kuzmin et al., 2008b)) and in Spain (Lleida bat 
lyssavirus, LLEBV, (Arechiga Ceballos et al., 2013) belonging to the Lleida bat lyssavirus 
species), respectively.  
In contrast to the Americas, CSTs are relatively rare in Europe. However, EBLV-1 CSTs have 
been documented in a number of occasions, including in a Dutch colony of captive Egyptian 
fruit bats (Rousettus aegyptiacus) (Wellenberg et al., 2002). Also, EBLV-1 has been detected 
in sheep from Denmark (Ronsholt, 2002), in a stone marten (Martes foina) in Germany 
(Müller et al., 2004) and two domestic cats in France (Dacheux et al., 2009).  
Sporadic human rabies cases following a bat bite have been described in Europe. In 1977, 
the first human rabies case associated with a bat bite in Europe was reported in the Ukraine 
(Kuzmin et al., 2006a). Another confirmed case in Russia that has been characterized was 
transmitted from a bat and occurred in 1985 (Selimov et al., 1989). The virus responsible for 
this infection was isolated and shown to be EBLV-1 (Amengual et al., 1997). 
A Swiss biologist who had multiple bat bites died in Finland in 1985. Rabies as a diagnosis 
was confirmed by laboratory tests and EBLV-2 was isolated for the first time (Lumio et al., 
1986). The second confirmed human rabies case with this lyssavirus was a 56-year-old bat 
conservationist from Angus, Scotland who died in November 2002 (Fooks et al., 2003). In all 
cases, the individual infected had a history of close contact with bats and none had received 
vaccination against rabies. 
 
2. BBLV - a novel bat lyssavirus isolated first in Germany 
In 2010, another novel lyssavirus named Bokeloh bat lyssavirus (BBLV) was isolated from a 
Natterer’s bat (Myotis nattereri) in Germany. The presence of lyssavirus antigens in the 
diseased bat was confirmed using fluorescence antibody test and immunohistochemistry 
with standard rabies biologics (Freuling et al., 2011). Two further viruses were isolated in 
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Germany and in France, respectively, 2 years later, all from the same bat species and all 
found in moribund or dead bats (Freuling et al., 2013; Picard-Meyer et al., 2013). 
Animal experimental studies demonstrated that BBLV was pathogenic for mice via 
intracranial and intramuscular inoculation routes, causing fatal encephalitis irrespective of 
the isolate used (Nolden et al., 2014). As typical to lyssaviruses during infection BBLV formed 
intracytoplasmic inclusions, detected by staining with FITC-conjugated anti-nucleocapsid 
monoclonal antibodies. Kaplan-Meyer survival plots were significantly different to EBLV-2 
and similar to EBLV-1, although BBLV is on a genetic level more closely related to the former 
(Nolden et al., 2014). The distinction between BBLV and other lyssavirus species was also 
evident in the antigenic patterns in reactions with anti-nucleocapsid monoclonal antibodies. 
This difference was supported by antigenic cartography where BBLV was separated from all 
characterized lyssaviruses, but related to phylogroup I viruses (Nolden et al., 2014). While 
the genome organization and sequence relationships are consistent with the classification as 
a lyssavirus, BBLV nucleotide sequences demonstrate 80% and 79% identity to the sequence 
of the most similar viruses KHUV and EBLV-2, respectively. Altogether, genetic distance, 
phylogenetic reconstructions, antigenic patterns and ecologic features were sufficiently 
different to existing lyssavirus species, and the creation of the Bokeloh bat lyssavirus species 
was approved (ICTV, 2015). 
2.1. The Natterer’s bat – the presumed primary host of BBLV 
For better understanding of virus-host interactions, i.e. between BBLV and the Natterer's 
bat, knowledge on their ecological and phylogenetic characteristics are essential. M. 
nattereri (Kuhl, 1818), synonym Myotis escalerae (Cabrera, 1904), is a middle-sized, crevice-
dwelling, nocturnal, insectivorous European bat species of the Western Palearctic belonging 
to the genus Myotis, subfamily Myotinae, chiropteran family Vespertilionidae of the 
suborder Vespertilioniformes. This bat was first described by the German naturalist and 
zoologist Heinrich Kuhl in 1818, who named it in honour of his Austrian colleague Johann 
Natterer (Beolens et al., 2009). Ancestors of M. nattereri can be traced back millions of years 
ago till the Pliocene (Sigé and Legendre, 1983). Paleontological evidence suggests an 
evolutionary segregation and subsequent development and adaptation of several subspecies 
at the beginning of the Holocene-Pleistocene (Horacek and Hanak, 1983; Hutterer et al., 
2012). Its geographic range extends throughout most of Europe, from the Atlantic Ocean 
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and the Mediterranean basin up to latitude of 60 degree north (Sweden, Finland) into 
western Russia, and Ukraine (Figure 1). Populations of M. nattereri also occur in western and 
south-western Asia Minor, the Caucasus region, the coastal regions of the Near East, the 
Kopetdag Mountains (Turkmenia, Iran) and northern Kazakhstan. Its historic range included 
Norway, in which for reasons unknown it is no longer found anymore. Presumably, 
Natterer’s bats do not occur on the islands of Sardinia, Malta and Kreta (Hutson et al., 2008; 
Topal, 2011). It can also be found in the western Atlas and coastal zones north-west Africa, 
although few records from north Africa indicate that the population is likely to be relatively 
small (Hutson et al., 2008). 
 
 
Fig. 1. Geographic origin of the BBLV isolates (left) in combination with the range (right in 
yellow) of the presumed reservoir species, the Natterer’s bat (Myotis nattereri). The case 
associated with a pipistrelle bat (Pipistrellus pipistrellus) is indicated (diamond). Also, the 
delineation into the two genetic lineages A (red) and B (blue) is shown in the left box. Source 
for the range data: Myotis nattereri In: IUCN 2012. IUCN Red List of Threatened Species. 
Version 2012.1. http://www.iucnredlist.org. Downloaded on 30 April 2017. 
 
 
Although M. nattereri occurs in various habitats from sea level up to an altitude of about 
2,000 meters, in the middle European inland it is predominantly found in open countryside 
with scattered broad-leaved woodland and close to water bodies such as tree-lined river 
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corridors (Smith, 2001) (http://www.eurobats.org). Natterer’s bats are generally considered 
a sedentary species (Schober and Grimmberger, 1998). In general, roost switching seems to 
be very common among M. nattereri, especially in summer times (Smith, 2001) with 
transboundary migration flows in border areas of European countries. Bat banding data from 
12 European countries reveal that migration distances between maternity, swarming and 
hibernation roosts usually vary according to region and climatic conditions (Hutterer et al., 
2005). While in southern Europe due to the moderate climate during winter times 
populations of Natterer’s bats are believed not to be forced to move from one roost to 
another (DePaz et al., 1986), migration distances between those roost sites of their northern 
conspecifics are reported to range between 14 and 90 km, on average (Topal, 2011). 
However, there is increasing evidence that this species is at least facultative migrant 
suggesting that this bat species is more a regional migrant than a true sedentary species 
(Hutterer et al., 2005). Based on registered one-way flights and return flights from winter to 
summer roost and between winter, summer and swarming sites some individuals are known 
to have covered longer distances. In Germany, long distance records (return flight from 
wintering roost) of 157 km (Haensel, 2004) and up to 266 km and even 327 km in a male and 
female for one-way flights, respectively, have been described. These unusual long 
movements are believed to be dispersal flights (Steffens et al., 2005).  
In the course of history, for the Natterer’s bat species, several subspecies and other 
potentially related species have been identified and proposed (for review see (Topal, 2011)). 
However, differentiating closely related species from another can represent a challenge 
(Padial et al., 2010; Shaffer and Thomson, 2007), because traditional taxonomy based on 
morphological characteristics can be misleading by the presence of phenotypic 
plesiomorphism or adaptative convergence (Salicini et al., 2011). With the advent of 
sophisticated genetic tools, molecular phylogenetics have been widely used to survey 
biological diversity of mammals, in particular Chiroptera, with results shedding new light on 
molecular systematics and taxonomy of species and their biogeography. In fact, the genetic 
biodiversity of the Natterer’s bat seems to be much more complex and is still not fully 
understood. Recent phylogenetic analysis based on nuclear and mitochondrial microsatellite 
loci revealed new phylogenetic relationships within the M. nattereri species complex (also 
referred to as M. nattereri sensu lato) and among closely related species (Puechmaille et al., 
2012). Evidence is mounting that there is much higher genetic variation in the M. nattereri 
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species complex than previously thought. M. nattereri in the Western Mediterranean, 
France and Germany, for example, was shown to be a paraphyletic group that is composed 
of well-differentiated lineages across regions, which have a narrower geographic distribution 
with potentially overlapping contact zones (Halczok et al., 2017; Ibanez et al., 2006; 
Puechmaille et al., 2012; Salicini et al., 2011). These lineages match clades partially described 
previously, e.g. M. nattereri sensu stricto, M. escalerae, clade A corresponding to Myotis sp. 
A and clade B corresponding to Myotis sp. B (Garcia-Mudarra et al., 2009; Ibanez et al., 2006; 
Mayer et al., 2007). According to the unified species concept which is proposing separately 
evolving metapopulation lineages as the only necessary property of species (De Queiroz, 
2007) some of these novel phylogenetic M. nattereri lineages could be considered as new 
cryptic species (Puechmaille et al., 2012; Salicini et al., 2011; Salicini et al., 2013). More 
research is needed however, to further substantiate these observations. 
 
3. Further investigation the presence of BBLV in bats in Germany and in France 
3.1. Bat lyssavirus surveillance 
In both countries, France and Germany, rabies surveillance in bats is based on a passive 
surveillance system. In Germany, due to the federal structure, animal disease detection 
including routine bat rabies surveillance is performed at regional veterinary laboratories 
focussing on clinically suspect animals and especially those with human contact. 
Furthermore, in order to increase submission numbers an enhanced passive surveillance was 
initiated in 1998 (Schatz et al., 2014), whereby dead bats from different sources and 
collections, e.g. conservation agencies, universities, private collections or museums were 
acquired. The submitting bat handlers morphologically delineated all submitted bats into 
species using phenotypical features (Dietz and von Helversen, 2004). In France, all bats 
associated with human contact are submitted for analysis to the National Reference Center 
for Rabies (NRC-R), at Institut Pasteur, Paris, whereas dead found bats without human 
contact are investigated by the National Reference Laboratory for Rabies, Anses-Malzeville. 
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3.2. Postmortem diagnosis of rabies in bats 
Similar to other rabies suspected animals, the postmortem diagnosis of rabies in bats is 
based on standard virological techniques. With the advent of molecular diagnostics, the 
rapid detection, confirmation, and differentiation of bat rabies isolates became possible and 
is additionally applied. (Box 1). 
Box 1. Rabies diagnostics 
Postmortem rabies diagnosis of bats is usually performed on brain samples using the 
fluorescent antibody test (FAT) as described (Dean et al., 1996). In brief, brain smears are 
fixed on slides and stained with fluorescein isothiocyanate (FITC) conjugates (Bio-Rad, 
Marnes-la-Coquette, France and SIFIN, Berlin, Germany). All FAT results in France and 
positive or questionable results in Germany are confirmed by the rabies tissue culture 
infection test (RTCIT) using mouse neuroblastoma cell lines (Neuro-2a, ATCC CCL-131 or 
MNA 42/13, FLI Cat. No.0229, respectively), essentially as described (Bourhy et al., 1989; 
Webster and Casey, 1996). RTCIT was performed using clarified brain suspension and 
homogenates from various other organs where available (Table 2). 
Viral RNA detection: RNA isolation in France was performed following manufacturer’s 
recommendations, from the brain suspensions or directly from organs following a 
digestion step (Dacheux et al., 2008), after immersion into 1mL of TriReagent or 0.8 mL of 
TriReagent LS (Molecular Research Center) respectively. Diluted RNA (1:10, in nuclease-
free water) was subjected to real-time RT-PCR (RT-qPCR) as previously described (Dacheux 
et al., 2016). In short, two RT-qPCRs were performed. The first was a probe-based 
(TaqMan) RT-qPCR for detecting the RABV species (pan-RABV RT-qPCR) and in the second 
RT-qPCR an intercalating dye (SYBR Green) was used for the detection of other lyssavirus 
species (pan-lyssa RT-qPCR). Furthermore, two conventional hemi-nested RT-PCRs 
targeting the nucleoprotein and the polymerase genes were performed as described 
(Dacheux et al., 2008; Davis et al., 2005), followed by Sanger sequencing of the respective 
amplicons for genotyping. In Germany 250 µl of the brain and organ homogenates were 
immersed into 750 µl of peqGOLD TriFast (peqlab) and RNA extraction was performed 
according to manufacturer’s instructions. The resulting RNA was eluted in 20 µl of 
nuclease-free water and subjected to multiplex R14 RT-qPCR as described elsewhere 
(Fischer et al., 2014) using the AgPath-IDTM One-Step RT-PCR Kit (Applied-Biosystems). 
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3.3. Characterization of positive specimens 
Historically, lyssaviruses were delineated based on reaction patterns of anti-nucleocapsid 
monoclonal antibodies (Schneider et al., 1985). The initial BBLV isolate was also subject to 
typing, confirming the antigenic distinction between BBLV and other lyssavirus species 
(Freuling et al., 2011). Furthermore, sequence comparisons allow for the inference of 
phylogenetic relationships and have been applied for lyssaviruses, including BBLV (Freuling 
et al., 2011; Picard-Meyer et al., 2013). Besides classical Sanger sequencing for bat species 
verification, next-generation sequencing (NGS) was applied to obtain full-length genome 
sequences of all available BBLVs (Box 2). 
Box 2. Sequencing 
For high quality full-length genome sequencing of the BBLV isolates the protocol described 
by (Nolden 2016) can be applied. Briefly, extracted RNA is transcribed into cDNA using the 
cDNA synthesis system kit (Roche) together with random hexamer primers (Roche). 
Subsequently, either Illumina or Ion Torrent compatible libraries are generated using the 
respective adapters. After size-selection, libraries are quantified and sequenced either on 
an Illumina MiSeq (Illumina) or Ion Torrent PGM (Life Technologies) instrument using 
MiSeq reagent kit v3 (Illumina) and HiQ-View chemistry (Life Technologies), respectively. 
Application of an iterative mapping and de-novo assembly approach using 454 Sequencing 
Systems Software [version 3.0; Roche] generates reliable BBLV consensus sequences from 
each isolate. Subsequently, the consensus sequences are annotated for instance using the 
Geneious software package (Kearse et al., 2012).  
An alternative sequencing protocol was described (Dacheux et al., 2010; Joffret et al., 
2013). Here, total RNA is reverse transcribed using Superscript III reverse transcriptase 
with random hexamers (Invitrogen) and amplified using QuantiTect Whole Transcriptome 
kit (Qiagen). Amplified cDNA is fragmented and libraries are prepared using KAPA Library 
Preparation Kit (Kapa Biosystems). The resulting libraries are subsequently sequenced on 
Illumina MiSeq running in 325 nt single-end modus. The obtained sequencing reads are 
pre-processed to remove low quality or artificial bases using AlienTrimmer (Criscuolo and 
Brisse, 2013) as implemented in Galaxy (Goecks et al., 2010). To obtain viral genome 
sequences, trimmed reads are mapped along appropriate reference sequences using CLC 
Genomics Assembly Cell (CLC bio) as implemented in Galaxy. Annotation of the derived 
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consensus sequence is performed using Sequencher 5.2.4 software (Gene Codes 
Corporation). 
For bat species determination partial or full cytochrome b (CYTB) sequences are used. 
These are usually obtained by Sanger sequencing essentially as described previously 
(Bickham et al., 2004; Schatz et al., 2014). To this end, wing membrane samples or brain 
material are used which are lysed overnight. Alternatively, CYTB-DNA is extracted from a 
patagium biopsy using the using DNeasy Blood and Tissue kit (Qiagen). CYTB-DNA is then 
amplified using specific primer pairs (CytB Uni fw and CytB Uni rev or LGL-765- F and LGL-
766-R). The obtained PCR fragments are seperated in a 1% agarose gel stained with 
ethidium bromide, purified using the QIAquick Gel Extraction Kit (Qiagen) and sequenced.  
Regardless of the protocol used, sequences are made publicly available by submission to 
one of the INSDC (International Nucleotide Sequence Database Collaboration) databases. 
From these databases, the sequences can be retrieved using their individual accessions 
(see for instance table 1). Alternatively, at the European Nucleotide Archive (part of the 
INSDC) sequences can combined into studies and be retrieved using a single study 
accession (see for instance PRJEB20392 for a number of BBLV and related CYTB 
sequences). 
 
3.4. Confirmation of further cases of BBLV 
In Germany, from 1998 until 2016 a total of 5591 bats were tested in the frame of enhanced 
passive surveillance, with the most frequently submitted bat species being the common 
pipistrelle bat (Pipistrellus pipistrellus) and the noctule bat (Nyctalus noctula). Of all samples, 
67 tested positive for lyssavirus antigen representing primarily EBLV-1 isolated from its 
reservoir host, the serotine bat. Also, a few infections in other bat species i.e., the common 
pipistrelle bat, the Nathusius’ pipistrelle bat (Pipistrellus nathusii) and the brown long-eared 
bat (Plecotus auritus) were found as reported before (Schatz et al., 2014). During the same 
period, five cases of BBLV infection were observed in Natterer’s bats (M. nattereri, Table 1, 
Fig. 1) and an additional case of BBLV infection was observed in the common pipistrelle bat, 
representing the first case of BBLV in a species other than a Natterer’s bat. The bat was 
initially found injured during daytime in December 2015 and was taken to a regional bat 
conservationist for rehabilitation and eventual return to the wild, but died 3 days later 
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without clear signs of a disease. The bat was subject of sampling in the frame of 
retrospective bat lyssavirus surveillance, and initial fluorescent antibody test results were 
corroborated by real-time RT-PCR specific for BBLV.  
In France during a 28-year period (from 1989 to 2016), a total of 546 dead bat specimens 
suspected of human exposure were received at the NRC-R for rabies diagnosis. Of those, 17 
were confirmed to be rabid after postmortem diagnosis and found to be infected by EBLV-1, 
with 4 EBLV subtype a and 12 EBLV subtype b. All of them were serotine bats (E. serotinus), 
except for one in 2005 which was identified as a common pipistrelle bat (P. pipistrellus) and 
for which viral RNA (EBLV-1b) and viral antigens by ELISA were detected (data from the NRC-
R). In 2013, a case of BBLV infection was diagnosed in a Natterer’s bat (M. nattereri) in La 
Bridoire (Table 1, Fig. 1). It represented the second case of BBLV infection in France in a 
Natterer’s bat, the first one being detected in 2012 (Picard-Meyer et al., 2013). Similar to the 
German BBLV isolates, all these isolates were detected using classical techniques for the 
post-mortem diagnosis of rabies. 
3.5. Virus distribution in BBLV infected bats 
Different tissue samples were tested for virus isolation by RTCIT and for viral RNA detection 
by RT-qPCR from BBLV infected bat specimens. Viable virus was isolated from all tested 
organs from the bat from Kronach (39608) and in 5/8 organs of the common pipistrelle bat 
from Elze (39068) (Table 2). In contrast, virus isolation was successful in four out of ten 
organs from the bat from Ebermannstadt (42052). Similarly to virus isolation, lyssavirus RNA 
was detected by RT-qPCR in all tested organs in the bat from Kronach (39607) and Elze 
(39068), and in 8/10 tested organs for bats from Ebermannstadt (42052) (Table 2). For the 
BBLV positive bat from La Bridoire (13001FRA), virus could only be isolated from brain and 
lyssavirus RNA were detected in brain and kidney (Table 2). 
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Table 1: Details on BBLV isolates including e.g. host, clinical signs and accession numbers. 
  
21
96
1
Fe
b
 1
0
B
o
ke
lo
h
, G
e
rm
an
y
ag
gr
e
ss
iv
e
ly
, d
ir
e
ct
ly
 a
p
p
ro
ac
h
in
g 
an
y 
m
o
vi
n
g 
o
b
je
ct
, v
ig
o
ro
u
sl
y 
tr
yi
n
g 
to
 b
it
e
, a
n
d
 s
cr
e
am
in
g 
fe
ro
ci
o
u
sl
y,
 g
e
n
e
ra
l w
e
ak
n
e
ss
, l
e
th
ar
gy
, a
n
d
 
p
ar
al
ys
is
. A
ft
e
r 
th
e
 f
ir
st
 3
 d
ay
s 
o
f 
th
e
 c
li
n
ic
al
 
co
u
rs
e
, t
h
e
 b
at
 s
to
p
p
e
d
 d
ri
n
ki
n
g 
an
d
 e
at
in
g 
10
 d
ay
s
JF
31
19
03
Fr
e
u
li
n
g 
e
t 
al
.,
 2
01
0
K
C
16
99
85
Ju
n
 1
2
H
e
m
il
ly
, F
ra
n
ce
p
ar
al
ys
is
, w
e
ig
h
t 
lo
ss
>2
 d
ay
s
K
C
16
99
85
P
ic
ar
d
-M
e
ye
r 
e
t 
al
.,
 2
01
3
29
00
8/
29
02
8
O
ct
 1
2
Li
ch
te
n
fe
ls
, G
e
rm
an
y
p
ro
m
in
e
n
t 
b
it
in
g 
b
e
h
av
io
r,
ag
gr
e
ss
iv
e
n
e
ss
, 
tr
e
m
o
r 
o
f 
th
e
 w
in
gs
 a
n
d
 w
as
 u
n
w
il
li
n
g 
to
 d
ri
n
k
6 
d
ay
s
K
F2
45
92
5
Fr
e
u
li
n
g 
e
t 
al
.,
 2
01
3
13
00
1F
R
A
A
u
g 
13
La
 B
ri
d
o
ir
e
, F
ra
n
ce
Fo
u
n
d
 d
e
ad
 b
y 
tw
o
 y
o
u
n
g 
ch
il
d
re
n
, w
h
ic
h
 
fu
rt
h
e
r 
re
ce
iv
e
d
 a
 p
o
st
-e
xp
o
su
re
 p
ro
p
h
yl
ax
is
N
/A
M
F0
43
18
8
39
60
7/
39
60
8
M
ay
 1
5
K
ro
n
ac
h
, G
e
rm
an
y
A
n
im
al
 w
as
 f
o
u
n
d
 g
ro
u
n
d
e
d
 a
n
d
 w
as
 t
ra
n
sf
e
rr
e
d
 
to
 a
 r
e
h
ab
il
it
at
io
n
 c
e
n
tr
e
 w
h
e
re
 it
 s
h
o
w
e
d
 o
ve
rt
 
ag
re
ss
iv
e
 b
e
h
av
io
r.
 E
ve
n
tu
al
ly
, t
h
e
 a
n
im
al
 d
ie
d
 
an
d
 w
as
 s
u
b
m
it
te
d
 f
o
r 
ra
b
ie
s 
te
st
in
g
N
/A
LT
83
96
17
39
06
8
P
ip
is
tr
el
lu
s 
p
ip
is
tr
el
lu
s
D
e
c 
15
El
ze
, G
e
rm
an
y
an
im
al
 w
as
 f
o
u
n
d
 g
ro
u
n
d
e
d
 d
u
ri
n
g 
d
ay
ti
m
e
 a
n
d
 
w
as
 c
ar
e
d
 f
o
r 
in
 a
 r
e
h
ab
il
it
at
io
n
 c
e
n
tr
e
. 
Ev
e
n
tu
al
ly
, t
h
e
 a
n
im
al
 r
e
fu
se
d
 t
o
 e
at
 a
n
d
 d
ri
n
k 
an
d
 d
ie
d
 w
it
h
o
u
t 
o
th
e
r 
cl
in
ic
al
 s
ig
n
s 
o
f 
ra
b
ie
s
>3
d
ay
s
LT
83
96
42
41
02
1
A
u
g 
16
Lü
n
e
b
u
rg
, G
e
rm
an
y
d
if
fi
cu
lt
y 
in
 s
w
al
lo
w
in
g,
 r
e
fu
se
d
 t
o
 e
at
 a
n
d
 
d
ri
n
k,
 m
o
ti
o
n
 s
ti
m
u
la
te
d
 v
o
ca
li
za
ti
o
n
,  
d
e
fe
n
si
ve
 w
in
g 
b
e
at
in
g
9 
d
ay
s
LT
83
96
44
42
05
2/
42
05
3
A
u
g 
16
Eb
e
rm
an
n
ss
ta
d
t,
 G
e
rm
an
y
an
im
al
 w
as
 f
o
u
n
d
 g
ro
u
n
d
e
d
 a
n
d
 d
ie
d
 t
h
e
 s
am
e
 
d
ay
, f
o
ll
o
w
in
g 
re
fu
sa
l t
o
 d
ri
n
k 
an
d
 e
at
>1
d
ay
LT
83
96
43
th
is
 c
h
ap
te
r
Is
o
la
te
-N
o
.
Sp
e
ci
e
s
D
at
e
Lo
ca
ti
o
n
C
li
n
ic
al
 s
ig
n
s
D
u
ra
ti
o
n
 o
f 
cl
in
ic
al
 s
ta
ge
R
e
fe
re
n
ce
V
ir
u
s 
A
cc
e
ss
io
n
 
N
u
m
b
e
rs
M
yo
ti
s 
n
a
tt
er
er
i
M
yo
ti
s 
n
a
tt
er
er
i
Results 
 
 
83 
Table 2: Virological investigations on tissue samples for different bats infected with BBLV 
(RT-PCR/RTCIT); n.a. = not analyzed 
 
3.6.Sequence and phylogenetic analyses 
Full-length genome sequences were obtained using NGS for the five new BBLV isolates (Box 
2) and were analyzed together with the three sequences already available (Table 1). 
Phylogenetic analysis of these eight genomes showed a differentiation of BBLV sequences 
into two lineages. Lineage A included BBLV isolates 21961, 39068, and 41021 from lower 
Saxony, Germany and the isolate KC169985 from Hemilly, France, whereas lineage B 
included BBLV isolates 29008, 39607, and 42052 from Bavaria, Germany and the isolate 
13001FRA from La Bridoire, France (Figs. 1-3). Nucleotide identity within lineage A was 
above 98.8% and within lineage B above 96.8%. The heterogeneity of 3.2% in lineage B is 
primarily caused by the genetically divergent isolate 13001FRA from La Bridoire, France, 
whereas the BBLV isolates from Bavaria (29008, 39608, and 42052) have a nucleotide 
identity of above 99.2%. The same applies to lineage A with the BBLV isolates from lower 
Saxony (21961, 39068, and 41021) having a nucleotide identity above 99.7%. Nucleotide 
Organ Isolate 
 
39068 
(Elze) 
39608 
(Kronach) 
13001FRA 
(La Bridoire) 
42052 
(Ebermannstadt) 
Brain +/+ +/+ +/+ +/+ 
Tongue +/+ +/+ -/- +/+ 
Kidney +/- +/+ +/- +/- 
Pectoral muscle +/+ +/+ -/- +/+ 
Lung +/+ +/+ -/- +/- 
Heart +/+ +/+ -/- +/- 
Liver +/- +/+ n.a. +/- 
Spleen +/- +/+ n.a. -/- 
Salivary gland n.a. +/+ n.a. -/+ 
Bladder n.a. +/+ n.a. n.a. 
Intestine n.a. n.a. -/- +/- 
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identities between the two lineages varied between 92.7% and 93.2%, depending on the 
isolates. 
 
 
 
Fig. 2. Phylogenetic relationship of BBLV isolates from available full-length genome 
sequences using Maximum Likelihood method. Following an alignment with MAFFT (Katoh 
and Standley, 2013), the genetic distances were calculated using GTR+G as the optimal 
substitution model with 1000 bootstrap replications as implemented in MEGA6 (Tamura et 
al., 2013). The tree is drawn to scale, with branch lengths measured in the number of 
substitutions per site. BBLV can be differentiated into two lineages: lineage A included BBLV 
isolates 21961, 39068, and 41021 from lower Saxony, Germany and the isolate from Hemilly, 
France, whereas lineage B included BBLV isolates 29008, 39608, and 42052 from Bavaria, 
Germany and the isolate 13001FRA from La Bridoire, France. 
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4.Discussion 
Since its first and recent discovery in 2010 in Bokeloh, Germany, five additional cases of 
BBLV were found in Germany and two in France. In contrast, most other recently discovered 
lyssaviruses from insectivorous bats, i.e. ARAV, KHUV, West Caucasian bat virus (WCBV), 
SHIBV and LLEBV, have all been detected only once (Banyard et al., 2013). Diagnostically, as 
with other lyssaviruses, all BBLV isolates have been detected by techniques used for the 
postmortem diagnosis of rabies, based on antinucleocapsid antibodies conjugated with 
fluorescent dyes. Evidently, modern molecular tools offer advantages, e.g. increased speed, 
sensitivity, and possibilities for genetic characterization (Fischer et al., 2012; Fooks et al., 
2012). Specifically, RT-qPCRs dedicated to large spectrum detection of lyssaviruses are now 
available and suitable for the diagnosis of emerging lyssaviruses such as BBLV (Dacheux et 
al., 2016). In addition, multiplex RT-qPCRs have improved the differentiation of bat rabies 
into the individual bat lyssavirus species (Fischer et al., 2014). Also, it was demonstrated 
before that undirected molecular detection methods were useful in identifying novel BBLV 
cases. The bat brain from the BBLV case from Lichtenfels, Germany (29008) was subjected to 
microarray analysis and in parallel to next generation sequencing (Freuling et al., 2013). 
Similarly, the brain sample of the bat infected with the French isolate 13001FRA was tested 
using a novel high-density resequencing microarray (called VirID), based on the two previous 
versions of the PathogenID microarray (Dacheux et al., 2010), and was successfully detected 
(data not shown). As for the previous versions, this detection was possible with the presence 
of conserved nucleotide region in the polymerase genes of prototype viruses comprising 
seven species of lyssavirus (namely RABV, LBV, MOKV, DUVV, EBLV-1, EBLV-2 and ABLV) and 
an artificial consensus sequence based on all of these species. 
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Fig. 3. Phylogenetic relationship of all lyssavirus species representatives and all BBLV isolates 
inferred using the Maximum Likelihood method based on the GTR model. A discrete Gamma 
distribution was used to model evolutionary rate differences among sites. The tree is drawn 
to scale, with branch lengths measured in the number of substitutions per site, and 
bootstrap values (1000 replication) shown next to the branches. Evolutionary analyses were 
conducted in MEGA6 (Tamura et al., 2013). Virus species’ associations to phylogroups I and II 
are also indicated. 
Phylogenetic analysis performed on the full-length genome sequences of all BBLV isolates 
known to date clearly demonstrated the presence of two different lineages among this 
lyssavirus species: lineages A and B, with nucleotide identities between them above 92%. 
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The spatial distribution of these two lineages is puzzling, as both lineages comprise isolates 
from France and Germany. However, on a regional scale all isolates from Bavaria cluster 
closely together, and the same can be observed for the isolates from Lower Saxony, while 
the French viruses appear more distinct (Figs. 1 and 2). 
At the bat host level, the distribution of BBLV lyssavirus at the late stage of the disease 
seems large and massive, because viral RNA and infectious virus were detected in several 
tissues and organs, including tongue, kidney, pectoral muscle, lung, heart, liver, spleen, 
salivary glands, bladder and intestine, confirming earlier studies in one bat from Lichtenfels, 
Germany (Freuling et al., 2013). This large distribution was found for Natterer’s bats as well 
as for the common pipistrelle bat. An exception was observed with the French bat, for which 
the presence of viral RNA was observed only in kidney and brain. This is probably the 
consequence of the poor general condition of this bat carcass. 
The sudden emergence of BBLV is somewhat puzzling as surveillance activities across Europe 
and particularly in Germany and in France have not much changed in the last few years. In 
fact, in Europe, more than 1,000 bat rabies cases have been reported, and no significant 
changes in reported numbers have been observed in recent years (Fig. 4).  
 
 
Fig. 4. Graph showing the annual number of bat rabies cases in Europe as reported to the 
database of the WHO Rabies Bulletin Europe. The years in which BBLV was detected are 
highlighted and the number of BBLV cases per year are indicated. 
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Although surveillance efforts were further encouraged by the Eurobats agreement in 2006 
(Anon, 2006), bat rabies surveillance in Europe remained heterogeneous (Schatz et al., 
2013). This may have contributed to the fact that all BBLV isolates were discovered in France 
and Germany, two countries in which continuous bat rabies surveillance has been performed 
for decades (Picard-Meyer et al., 2014; Schatz et al., 2014). However, heterogeneous 
surveillance on a spatial level does not explain the number of novel cases of BBLV observed. 
Also, there is no indication that bat rabies cases in Natterer’s bats were found in the past 
that had not been characterized (Brass, 1994; Kappeler, 1989; Schatz et al., 2013). 
In Germany, besides routine surveillance targeting suspect animals and public health related 
incidents, in 1998 enhanced passive surveillance was started to include bats, which would 
otherwise be missed for lyssavirus surveillance. In total, the combined surveillance efforts 
resulted in sampling of 8,310 bats, with the most submitted bat species being the common 
pipistrelle. Although the pipistrelle bat is not considered as a primary host for any known bat 
lyssavirus species, three lyssavirus infections were discovered in this bat species. One was a 
case of EBLV-1 infection as described before (Schatz et al., 2014). A similar infection of EBLV-
1 in common pipistrelle bat was observed in France (data from the NRC-R). The other was 
the case of BBLV in a common pipistrelle from Elze described here. The latter represents the 
first evidence of BBLV in another bat species apart from the Natterer’s bat. All other cases of 
BBLV were discovered in Natterer’s bats, leading to the assumption that this bat species is 
the primary host for BBLV. When material was available, bats species were determined by 
partial CYTB gene sequencing, since bat species determination due to morphological 
features can be challenging, especially when dealing with cryptic species. Also, when 
carcasses arrive in the laboratory, they may be incomplete or in a state of degradation, thus 
making it difficult to verify the bat species. Indeed, the Natterer’s bat from Ebermannstadt, 
Germany was initially thought to be a Daubenton’s bat and only phylogenetic analysis of 
partial CYTB sequence revealed that it was in fact a Natterer’s bat (Fig. 5). Besides bat 
speciation, the combined molecular analysis of both host and virus is also essential for 
drawing further epidemiological conclusions, as exemplified for RABV in arctic foxes from 
Greenland (Hanke et al., 2016). 
As indicated previously, full-length analyses demonstrated that two distinct lineages of BBLV 
circulate among European Natterer’s bats. On the host side, recent phylogenetic analyses 
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revealed a much higher genetic variation in the M. nattereri species complex than previously 
thought. In Central Europe, M. nattereri was shown to be a paraphyletic group that is 
composed of four well-differentiated lineages, i.e. M. nattereri sensu stricto, M. nattereri 
escalerae, M. nattereri sp. A, and M. nattereri sp. B. (Halczok et al., 2017; Ibanez et al., 2006; 
Puechmaille et al., 2012; Salicini et al., 2011; Salicini et al., 2013). All Natterer’s bats found 
positive for BBLV belong to the subspecies M. nattereri sensu stricto (Fig. 5), which is not 
surprising, as this subspecies is known to occur in Germany and France (Salicini et al., 2011; 
Salicini et al., 2013). However, the distinct two lineages of BBLV do not seem to be related to 
a circulation in specific Natterer’s bat subspecies. 
In a recent study correlating genetic distances of Natterer’s bats and their associated 
astroviruses, identical astrovirus haplotypes were not shared between different sampling 
regions suggesting that astroviruses are mostly transmitted among host colonies at regional 
scale. The fact that some virus haplotypes found in several different regions had high genetic 
similarity implied that occasional transmission across regions occurred (Halczok et al., 2017). 
However, against the background that this bat species is a regional migrant species (Hutterer 
et al., 2005), the same can be assumed for BBLV, where the respective outliers could be a 
result of yet not documented long-distance migration. Evidently, for BBLV this analysis is 
restricted to the available dataset and further isolations may support this delineation. 
Interestingly, the same observation was made with EBLV-1 in serotine bats where almost 
identical nucleotide sequences from within certain geographical regions of the Netherlands 
and Germany indicate genomic stability during the transmission cycle of these virus variants 
but with occasional geographic spread or intermixing (Freuling et al., 2012; Poel et al., 2005). 
However, on a European scale there seems to be no clear correlation between migration 
behaviour of lyssavirus reservoir species and the phylogeographical clustering of virus 
isolates. For EBLV-1, the primary host serotine bat is a rather sedentary species, which is not 
reflected in the clustering of isolates (Davis et al., 2005). On the other hand, the Daubenton’s 
bat as the reservoir for EBLV-2 can migrate over larger distances. However, sequence 
analysis for EBLV-2 revealed a strong geographical clustering (Jakava-Viljanen et al., 2010). 
Further research, including and combining host biology, migration data, as well as molecular 
characterization of host and virus is essential to understand transmission dynamics and gain 
further insights into the epidemiology of bat-virus interaction. This may contribute to predict 
virus spread and establish risk assessments for virus transmission to humans. 
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Fig. 5. Phylogenetic relationship of partial CYTB sequences (484 nt) of bats found positive for 
BBLV and representatives of Myotis nattereri clades (Salicini et al., 2011; Salicini et al., 2013). 
While the bat from Elze (Lower Saxony) was identified as a common pipistrelle bat 
(Pipistrellus pipistrellus), all other bats found positive for BBLV were closely related and 
classified as Natterer’s bats (Myotis nattereri), and more precisely belong to the Myotis 
nattereri sensu stricto clade/subspecies. Phylogenetic analysis was inferred by using the 
Maximum Likelihood method based on the Hasegawa-Kishino-Yano model (HKY) with 
invariant sites (G) conducted in MEGA6 (Tamura et al., 2013). The tree is drawn to scale, 
with branch lengths measured in the number of substitutions per site, and bootstrap values 
(1000 replication) shown next to the branches. 
 
 
BBLV was shown to be as pathogenic in mice as EBLV-1 (Nolden et al., 2014) and it can be 
assumed that BBLV infections in humans potentially lead to an encephalitis eventually 
causing death. Therefore, BBLV alongside with the other known bat lyssaviruses in Europe 
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represents a low but undeniable public health threat. Unlike other remote regions in the 
world where people do not get into close contacts with bats, in Europe research and species 
conservation programs require the handling of bats by bat workers. While in the eastern 
parts of Germany the cumulative number of bat handlings from 2000-2010 for serotine bats 
were 1,260, those for M. daubentonii and M. dasycneme were 22,245 and 1086, 
respectively, with 37,140 by far the most handlings were recorded for the Natterer’s bat (Bat 
Marking Centre, Dresden). This underlines the importance of adequate prophylaxis for bat 
handlers. In addition, accidental exposure to bats could occur for individuals other than bat 
handlers. For example in 2015, a total of 128 patients consulted an antirabic clinic (ARC) in 
France after being exposed to a bat in France metropolitan, representing 2.6% of the total 
number of patients consulting such clinic (n=8,336) (data from NRC-R, available at (Pasteur, 
2017)). Some of these patients could be exposed to laboratory confirmed rabid bats, as it 
was the case for the two children who were in contact with the BBLV infected bat from La 
Bridoire, France. Considering the relatedness of BBLV to other members of the phylogroup I 
lyssaviruses (Figure 3) it appears likely that persons who received rabies prophylaxis will be 
protected. In fact, a recent study showed that available human inactivated vaccines elicit an 
antibody response that cross-neutralizes BBLV and therefore, are considered to confer 
protection against BBLV and other European bat lyssaviruses (Malerczyk et al., 2014; Nolden 
et al., 2014). Similarly, serum samples from French patients preventively vaccinated against 
rabies were analysed for the potency of neutralization against the CVS rabies strain (used as 
the reference virus) and 13001FRA isolate adapted to cell-culture. Seroneutralization of 
BBLV was observed, but with a 5.8-fold decrease compared to CVS (Fig. 6). In any case, as 
there are currently no other vaccines available (Evans et al., 2012), consistent preventive 
vaccination of all persons working with bats and PEP of all persons exposed to bats should be 
given priority as recommended in France (Haut Conseil de la santé publique, 2013; Lafeuille 
et al., 2005) and Germany (Delere et al., 2011).  
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Fig. 6. Comparison of seroneutralization against RABV (CVS) and BBLV (13001FRA) with 37 
sera of patients vaccinated against rabies using a modified RFFIT (Feyssaguet et al., 2007). 
The dilution value to obtain a 50% viral inhibition is visualized as box-plots, with the first, 
third quartiles are indicated at the bottom, and top of the box, respectively, and the median 
is indicated with the band. The neutralizing activity was found to be significantly lower 
(paired Student t test, p value < 0.05) against BBLV (mean value = 157, standard deviation = 
137) compared to CVS (mean value = 907, standard deviation = 623), with a 5.8 fold 
decrease in the titre dilution. 
 
 
Despite the recent discovery of a novel bat lyssavirus, lyssaviruses have been characterized 
in only a small proportion of recognized species (Banyard et al., 2013). Future surveillance of 
bat-associated pathogens using highly sensitive and novel high-throughput technologies, e.g. 
NGS (Dacheux et al., 2014) or pan viral microarrays, will likely increase the number of 
detected pathogens including novel lyssavirus species. This may also lead to further 
discoveries of BBLV in countries along the distribution of the Natterer’s bat. 
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5.3. Evaluation of six commercially available rapid immunochromatographic 
tests for the diagnosis of rabies in brain material 
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Supplementary Table 1: Diagnostic results of archived field samples tested in 2008 using 
the Bionote LFD (Cat.No.:RG 18-01; Lot NO.:1801029)
 
FAT and the LFDs were only regarded positive (+) or negative (-) without scoring the intensity 
 
  
Lab-ID species year Origin
Viral 
species
Lineage Material FAT-Result Bionote
148 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
149 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
150 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
151 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
152 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
153 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + -
154 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
155 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
156 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + -
280 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
281 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
282 Sheep 1998 Germany RABV Cosmopolitan (WE) brain  + -
284 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
285 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
286 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
287 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
288 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
289 Marten 1998 Germany RABV Cosmopolitan (WE) brain  + +
290 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
291 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
292 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
293 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + +
904 Dog 1998 Germany RABV Cosmopolitan (WE) brain  + +
1390 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + -
1391 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + -
1392 Fox 1998 Germany RABV Cosmopolitan (WE) brain  + -
5989 Dog 2002 Aserbaijan RABV Cosmopolitan (WE) brain  + +
16854 Fox 2007 Kosovo RABV Cosmopolitan (WE) brain  + +
16862 Fox 2007 Kosovo RABV Cosmopolitan (WE) brain  + +
17039 Fox 2007 experimental RABV Cosmopolitan brain  + +
17040 Fox 2007 experimental RABV Cosmopolitan brain  + +
6214 Ferret 2002 experimental EBLV-1 - brain  + +
6215 Ferret 2002 experimental EBLV-1 - brain  + +
6216 Ferret 2002 experimental EBLV-1 - brain  + +
6217 Ferret 2002 experimental EBLV-1 - brain  + +
10280 Sheep 2004 experimental EBLV-1 - brain  + +
10282 Sheep 2004 experimental EBLV-1 - brain  + +
10285 Sheep 2004 experimental EBLV-1 - brain  + +
10271 Sheep 2004 experimental EBLV-2 - brain  + +
10274 Sheep 2004 experimental EBLV-2 - brain  + +
10277 Sheep 2004 experimental EBLV-2 - brain  + +
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Supplementary Table 2: Diagnostic results of archived field samples tested in Italy using 
the Bionote LFD (Lot NO.: 1801077, 1801081) 
 
 
ID number Animal species Origin Viral species Lineage FAT result
RIDT 
result
RTCIT RT-PCR
303/2010 badger Italy RABV Cosmopolitan (WE) pos neg pos pos
450/2010 cat Italy RABV Cosmopolitan (WE) pos neg pos pos
527/2010 roe deer Italy RABV Cosmopolitan (WE) pos pos pos pos
836/2010 equine Italy RABV Cosmopolitan (WE) pos neg pos pos
1546/2010 cat Italy RABV Cosmopolitan (WE) pos pos pos pos
2174/2010 red fox Italy RABV Cosmopolitan (WE) pos neg pos pos
2176/2010 red fox Italy RABV Cosmopolitan (WE) pos neg pos pos
2177/2010 red fox Italy RABV Cosmopolitan (WE) pos pos pos pos
2418/2010 roe deer Italy RABV Cosmopolitan (WE) pos pos pos pos
2944/2010 red fox Italy RABV Cosmopolitan (WE) pos pos pos pos
3144/2010 stone marten Italy RABV Cosmopolitan (WE) pos neg pos pos
6944/2009 red fox Italy RABV Cosmopolitan (WE) pos neg* pos pos
7024/2009 red fox Italy RABV Cosmopolitan (WE) pos neg pos pos
117/1996 human (ex-dog) Italy (ex-Nepal) RABV Arctic-like 1 pos neg* pos pos
3570/2011 human (ex-dog) Italy (ex-India) RABV Arctic-like 1 pos neg* neg pos
1920/2005 dog Mauritania RABV Africa 2 pos neg pos pos
2019/2006 dog Mauritania RABV Africa 2 pos neg pos pos
2029/2007 dog Mauritania RABV Africa 2 pos neg pos pos
2049/2007 goat Mauritania RABV Africa 2 pos neg pos pos
1916/2005 goat Mauritania RABV Africa 2 pos neg pos pos
2871/2009 bovine Botswana RABV Cosmopolitan (Africa 1) pos neg* pos pos
4125/2009 bovine Botswana RABV Cosmopolitan (Africa 1) pos neg pos pos
3580/2009 dog Botswana RABV Cosmopolitan (Africa 1) pos pos pos pos
3416/2009 goat Botswana RABV Cosmopolitan (Africa 1) pos pos pos pos
5980/2009 dog Botswana RABV Cosmopolitan (Africa 1) pos pos pos pos
6665/2009 honey badger Botswana RABV Cosmopolitan (Africa 3) pos neg* pos pos
251/2007 dog Niger RABV Africa 2 pos neg pos pos
252/2007 dog Niger RABV Africa 2 pos neg pos pos
246/2007 dog Niger RABV Africa 2 pos neg pos pos
247/2007 dog Niger RABV Africa 2 pos neg pos pos
137/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
70/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
20/2007 dog Burkina Faso RABV Africa 2 pos pos pos pos
19/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
21/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
37/2007 dog Burkina Faso RABV Africa 2 pos pos pos pos
144/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
124/2007 dog Burkina Faso RABV Africa 2 pos pos pos pos
36/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
139/2007 dog Burkina Faso RABV Africa 2 pos pos pos pos
49/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
28/2007 dog Burkina Faso RABV Africa 2 pos neg pos pos
4314/1993 badger Italy RABV Cosmopolitan (WE) pos neg n.e. pos
786/1993 chamois Italy RABV Cosmopolitan (WE) pos neg n.e. pos
629/1993 cat Italy RABV Cosmopolitan (WE) pos neg n.e. pos
4313/1993 marten Italy RABV Cosmopolitan (WE) pos neg n.e. pos
4241/1993 red fox Italy RABV Cosmopolitan (WE) pos neg n.e. pos
EURL PT2012/1 (Ariana 1991 ) dog Tunisia RABV Cosmopolitan (Africa 1) pos neg pos pos
EURL PT2012/2 (EBL2-VLA P3 ) mouse (ex M. daubentonii) UK EBLV-2 pos neg pos pos
EURL PT2012/3 (201020958 ) mouse (ex dog) Spain RABV Cosmopolitan (Africa 1) pos pos pos pos
EURL PT2012/7 (GS7) red fox France RABV Cosmopolitan (WE) pos neg pos pos
EURL PT2012/8 (GS7) red fox France RABV Cosmopolitan (WE) pos neg pos pos
EURL PT2012/9 (R75) mouse (ex E. serotinus) Spain EBLV-1 pos neg pos pos
351/2010 bovine Brazil RABV American indigenous pos neg* n.e. pos
299/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
134/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
451/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
87/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
227/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
251/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
211/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
9/2010 bovine Brazil RABV American indigenous pos neg n.e. pos
77/2010 bovine Brazil RABV American indigenous pos pos n.e. pos
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*Samples resulted positive when tested with a different protocol which skipped the first 
dilution step 
 
  
ID number Animal species Origin Viral species Lineage FAT result
RIDT 
result
RTCIT RT-PCR
158/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
125/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
285/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
218/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
101/2011 equine Brazil RABV American indigenous pos neg n.e. pos
283/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
303/2011 bovine Brazil RABV American indigenous pos pos n.e. pos
62/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
320/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
196/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
144/2011 bovine Brazil RABV American indigenous pos neg n.e. pos
5B1/2011 kinkajou Brazil RABV American indigenous pos neg* pos pos
343/2011 equine Brazil RABV American indigenous pos neg* n.e. pos
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Supplementary Table 3: Comparison of two batches of BioGen LFD (Batch 1: Lot NO: 
AI191301, Batch 2: Lot NO: AI191402) using archived field samples (MP=mouse brain) 
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Supplementary Table 4: Comparison of between results obtained with sample set III in the 
laboratories at Onderstepoort (SA) and Friedrich-Loeffler-Institut (FLI) 
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Supplementary Table 5: Results of tissue culture supernatant tested in 2008 using the 
Bionote LFD (Cat.No.:RG 18-01; Lot NO.:1801029) 
 
 
 
  
Virus 
Titre 
(TCID50/ml) 
Undiluted 1:10 1:100 1:1000 1:10000 1:100000 1:1000000 
CVS 10
6.5
 
 
+ - - - - - - 
         
EBLV-1 10
6.2
 + + - - - - - 
         
         
EBLV-2  10
4.2
 + - - - - - - 
Discussion 
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6.Discussion 
Rabies still poses a human health threat almost worldwide. The greatest burden is carried by 
Asia and Africa, where dog-mediated rabies is responsible for the majority of human deaths 
caused by rabies (WHO, 2013a). Rabies surveillance in these regions is hampered by 
challenges in rabies diagnosis (Banyard et al., 2013). Lyssaviruses also circulate in bat 
populations and have been detected in many areas of the World including Europe (Schatz et 
al., 2013a). Although bat rabies surveillance in parts of Europe give an insight into the 
epidemiology of bat lyssaviruses, little is known about the transmission and maintenance of 
lyssaviruses in bat colonies (Freuling et al., 2009a). Previous surveillance revealed that EBLV-
1 is the most common lyssavirus present in Europe and that there is genomic variation 
within this lyssavirus species in the form of sublineages and indels (Freuling et al., 2012, 
Johnson et al., 2007, Amengual et al., 1997). Human deaths due to bat mediated rabies in 
Europe have been reported and therefore it is important to monitor the epidemiological 
situation (Fooks et al., 2003a). Furthermore, investigation of the respective lyssaviruses, e.g. 
their pathogenicity, is important to assess their zoonotic potential. 
 
Assessment of EBLV-1 pathogenicity: 
The low spill-over rate of EBLV-1 from bats to animals and humans compared to RABV, 
where spill-over infections occur more frequently, presents a conundrum (Johnson et al., 
2010, Kuzmin et al., 2012, Schatz et al., 2014a). Possible explanations include differences in 
host densities and contact rates of the reservoirs with terrestrial animals and humans, as 
well as the properties of the viruses (Freuling et al., 2009a). Pathogenicity studies in various 
animal species indicate that their susceptibility to EBLV-1 may be limited, however the 
results were obtained using single isolates (Cliquet et al., 2009, Brookes et al., 2007, 
Tjornehoj et al., 2006, Vos et al., 2004b, Vos et al., 2004a). Previously the pathogenicity of 
LBV was underestimated, based on limited data for only one isolate that indicated an 
apathogenic phenotype, following peripheral inoculation (Badrane et al., 2001). However, 
later investigations with other LBV isolates showed that this was not true (Markotter et al., 
2008). 
Discussion 
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Therefore, in order to assess the impact of natural genetic variation on EBLV-1 
pathogenicity, selected isolates were compared under standardised conditions in a mouse 
model. The results demonstrate that differences between the EBLV-1 isolates exist, 
regarding their pathogenicity as well as their incubation periods. These results need to be 
considered for the interpretation of previous studies, including studies where the 
pathogenicity of different lyssaviruses was compared. In previous experimental studies, all 
lyssaviruses present in Germany were shown to be pathogenic. EBLV-1 displayed higher 
mortalities in mice and ferrets following peripheral inoculation compared to EBLV-2, while 
the pathogenicity of EBLV-1 in mice was comparable to BBLV (Vos et al., 2004a, Nolden et 
al., 2014). The EBLV-1 isolate used by Vos et al. is identical to the EBLV-1 isolate 
13454_EBLV-1a, while in the study by Nolden et al. another EBLV-1 isolate was investigated, 
but under the same experimental conditions as in this thesis. This second EBLV-1 isolate 
displayed comparable pathogenicity to isolate 5782_EBLV-1a_del (Nolden et al., 2014). The 
other seven EBLV-1 isolates investigated in this thesis were less pathogenic, with 100% 
survival rates after intramuscular (i.m.) inoculation with low doses. This suggests, that at 
least for this animal model, i.e. 3 week old Balb/c mice, EBLV-2 and BBLV are in fact more 
pathogenic than EBLV-1. Interestingly isolate 13454_EBLV-1_ref, less pathogenic than EBLV-
2 in Balb/c mice, displayed higher mortalities in mice and ferrets following peripheral 
inoculation (Vos et al., 2004a). However, different EBLV-2 isolates might have been used in 
the two investigations and there might be differences in the pathogenicity of the isolates. 
Therefore, investigation of these and other EBLV-2 and BBLV isolates under the same 
experimental conditions are warranted. Furthermore, different animal models were used in 
those studies, i.e. Balb/c mice, CD1-mice and ferrets (Nolden et al., 2014, Vos et al., 2004a), 
and it is known that the pathogenicity of lyssaviruses depends on the animal species 
(Jackson and Fu, 2013). Since in this thesis, a very sensitive model, i.e. not fully 
immunocompetent mice, was used to detect even slight differences in the properties of the 
isolates, it is unclear whether these differences also apply to other animal species, including 
the natural reservoir for EBLV-1. Therefore, these results can provide only an indication how 
these viruses might behave in their reservoirs or in humans. Two studies assessed the 
pathogenicity of EBLV-1 in bats, i.e. in the serotine bat, as the reservoir species, and the big 
brown bat (Eptesicus fuscus), a bat species related to the serotine bat. In both studies, 
following peripheral inoculation with EBLV-1 mortalities were below 57% depending on 
Discussion 
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inoculation route and dose (Freuling et al., 2009b, Franka et al., 2008). To determine if the 
EBLV-1 isolates would also display differences in pathogenicity, when inoculated into their 
reservoir host, further studies are warranted, but difficult to implement due to the protected 
status of European bats (UNEP/EUROBATS, 1994).  
A correlation between the inoculation route, the clinical signs as well as the virus distribution 
in the brain was observed, with the virus distribution in different brain regions, as well as the 
clinical signs being dependent upon the inoculation route. Although previous studies 
examined distribution of EBLV-1, EBLV-2 and RABV in different brain regions, the viruses 
were always inoculated into the left hind footpad. Thus the impact of the inoculation route 
on virus distribution was not assessed (Hicks et al., 2009, Healy et al., 2013). In these studies, 
virus antigen was most frequently observed in the pons and rostral medulla, followed by the 
cortex 3, hypothalamus and thalamus (Hicks et al., 2009). The highest quantity of virus 
antigen was present in the pons and rostral Medulla (Healy et al., 2013). No difference 
between the lyssavirus species could be observed (Hicks et al., 2009, Healy et al., 2013). 
These results are concordant to the results presented here, as following i.m. inoculation the 
medulla contained most virus antigen and no difference in virus distribution between the 
RABV isolate and the EBLV-1 isolates could be observed. The high antigen content in the 
medulla following intranasal (i.n.) inoculation could be due to the development of clinical 
signs at a later stage of infection. Another possibility would be that the virus following i.n. 
inoculation does not just spread via the olfactory nerve, but also via sensory neurons of the 
ophthalmic nerve and subsequent trigeminal nerve as described previously (Lafay et al., 
1991, Hronovsky and Benda, 1969a). In one study, following i.n. inoculation with EBLV-2 and 
RABV, virus was detected in the lung, stomach and tongue, indicating that the inoculum gets 
swallowed and aspirated, which could result in multiple routes of entry (Johnson et al., 
2006). Although the inoculum used in this thesis was considerably smaller (10µl compared to 
30µl), the possibility of another entry route cannot be entirely ruled out (Johnson et al., 
2006).  
While a number of i.m. infected mice developed antibodies, there was a complete absence 
of seroconversion following i.n. inoculation. Although this had been described previously in 
tested survivors of a mouse study after inoculation with EBLV-2 and RABV, survivors of a 
study where guinea pigs were infected via aerosol with a RABV strain developed antibodies 
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(Hronovsky and Benda, 1969b, Johnson et al., 2006). The absence of antibodies supports the 
theory, that after i.n. inoculation the virus directly enters the nervous system via olfactory or 
sensory neurons, without inducing an immune response. Generally no correlation between 
survival and seroconversion of the mice was observed following i.m. inoculation with EBLV-1, 
which is concordant with previous results, where even after four subsequent multiple 
peripheral exposures of mice to EBLV-1, EBLV-2 and RABV over a period of ca. 3 months 
seroconversion in survivors did not always occur (Banyard et al., 2014b). Similar 
observations were also made in bats as the reservoir hosts of lyssaviruses. Following s.c. 
infection of big brown bats and serotine bats with EBLV-1, seroconversion of all or none of 
the infected animals was observed, respectively (Franka et al., 2008, Freuling et al., 2009b). 
Furthermore, antibody titres in bats seem to drop within a year, as demonstrated in studies 
using ABLV and RABV (McColl et al., 2002, Turmelle et al., 2010). 
The results suggest, that seroconversion after exposure to lyssaviruses does not always 
occur in mice and bats, and that in the latter antibody titres tend to drop relatively soon 
following infection, although the animals are still protected (Turmelle et al., 2010). This 
needs to be taken into consideration for the interpretation of serological results during 
active surveillance studies in bats (Banyard et al., 2011). The seroprevalence of lyssavirus 
antibodies in bats in Europe varies (Schatz et al., 2013a). Estimating the prevalence of bat 
lyssaviruses in Europe from these serologic results is difficult, considering that there is 
evidence, that seroconversion following exposure to lyssaviruses does not always occur and 
is not of long duration. Coupled with afore mentioned difficulties, i.e. non-standardized 
serological test procedures and cross-neutralization of phylogroup 1 lyssaviruses, active 
surveillance can provide only limited information (Freuling et al., 2009a, Schatz et al., 
2014a). 
 
Enhanced passive bat rabies surveillance in Germany: 
Passive bat rabies surveillance is the method of choice to obtain information on bat rabies 
epidemiology (Freuling et al., 2009a, Schatz et al., 2014a). The continued isolation of EBLV-1, 
EBLV-2 and BBLV shows that routine surveillance as well as enhanced passive bat rabies 
surveillance contribute to the understanding of the epidemiology of bat lyssaviruses in 
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Germany. Although the majority of bat rabies cases were detected during routine 
surveillance, enhanced passive bat rabies surveillance provides additional information, 
through the detection of bat rabies cases which would otherwise be missed, and also gives a 
better estimate of the true prevalence of bat lyssaviruses in Germany. For example the spill-
over case of BBLV in the common pipistrelle in 2015, described in this thesis, was only 
detected during enhanced passive bat rabies surveillance. The discovery of two further BBLV 
cases within a year doubled the number of BBLV cases detected in Germany. This sudden 
emergence of BBLV represents somewhat of a mystery. BBLV seems to be as or even higher 
pathogenic than EBLV-1, at least in the mouse model used here. As human spill-over cases 
have been described for EBLV-1 (Fooks et al., 2003a, Selimov et al., 1989), the zoonotic 
potential of BBLV should also not be underestimated. BBLV RNA was present in various 
organs of the BBLV infected bats, suggesting wide-spread virus distribution at the host level. 
Similar observations were made in naturally EBLV-1 infected serotine bats, EBLV-2 infected 
Daubenton's bats and RABV infected non-hematophagous bats (Schatz et al., 2014b, 
Allendorf et al., 2012). Interestingly, in an EBLV-1 spill-over case of a Nathusius' pipistrelle 
bat, virus RNA was only detected in the heart and replication competent virus could be 
isolated only from the brain (Schatz et al., 2014b). In comparison, BBLV RNA was detected in 
all tested organs and viable virus in 5 out of 8 organs of the common pipistrelle bat. These 
results indicate that lyssavirus distribution from the central nervous system to various 
peripheral organs is apparently common for natural infected bats. Virus was isolated from 
the salivary glands of two investigated bats and since the presence of viable virus in the 
salivary glands is of outmost importance for onward transmission, this supports the potential 
of BBLV to cause spill-over infections.  
The pathogenicity of BBLV has been investigated using two isolates (21961-Bokeloh, 29008-
Lichtenfels) with a nucleotide identity of 92.9%, which cluster into the two separate 
sublineages A and B proposed here. No difference in the pathogenicity of the BBLV isolates, 
was observed (Nolden et al., 2014) although one AA exchange (His523Gln) in the 
glycoprotein is present in a potential pathogenicity determining site (Babault et al., 2011, 
Prehaud et al., 2010). This AA exchange is so far only present in BBLV isolates from Lower 
Saxony. No other AA exchanges were observed in known pathogenicity determining sites of 
the BBLV isolates (For references see S4 table, EBLV-1 paper). Overall the data obtained so 
far provide no indication that BBLV isolates differ in their pathogenicity, although the same 
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was true for EBLV-1 where differences in the pathogenicity of isolates were discovered. 
Here, continuing surveillance for BBLV and investigation of novel isolates is of importance. 
Passive bat rabies surveillance is also important for determining the diversity and evolution 
of lyssavirus isolates by genetic analyses and in vitro and in vivo studies. By isolation and 
archiving of isolates, these are available for further investigations, e.g. determination of the 
impact of genetic variation on the pathogenicity as described in the previous section. The 
results of such investigations provide important information for the assessment of the 
human health threat posed by endemic lyssaviruses. Bat rabies control is not feasible in 
Europe and has so far only been performed for RABV in Vampire bats in America (Kuzmin 
and Rupprecht, 2015). These programs focus of on the reduction or elimination of vampire 
bat populations through culling, but there are strong indications that these measures are 
counterproductive and in the long term result in a dispersal of the bats and reduction in 
seroprevalence (Johnson et al., 2014). Population reduction in European bats would be 
ineffective and is due to their protected status not an option (Kuzmin and Rupprecht, 2015). 
 
LFDs as a tool for rabies surveillance in developing countries: 
Control of dog-mediated rabies and subsequent elimination has already been performed 
successfully. This could greatly reduce the number of human rabies cases, as rabid dogs 
present the main source for human infection (Müller et al., 2012). However, in developing 
countries in Asia and Africa, which are most affected, diagnosing rabies is challenging 
(Banyard et al., 2013). Therefore, LFDs as an alternative diagnostic tool for rabies were 
developed and six commercially available LFDs were evaluated in this thesis.  
Unfortunately, the performance of the LFDs was not satisfactory, as test agreement of the 
LFDs, with the gold standard FAT, for experimentally infected animals and archived field 
samples were low (Kappa < 0.37). Only for field samples from South Africa test agreement 
between four of the LFDs and FAT was good to perfect (Kappa 0.72-1.00). Overall, 
investigated LFDs displayed insufficient sensitivities and reproducibility. These are known 
weaknesses of traditionally designed LFDs and can be caused by the materials incorporated 
in the LFD, their treatment and the final assembly of the test strip (O’Farrell, 2013). For 
example the nitrocellulose membrane and its treatment, as well as the conjugate pad 
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material and the many processing steps required for conjugate application can have a 
notable impact on the reproducibility of LFDs (O’Farrell, 2013, Posthuma-Trumpie et al., 
2009). There was no information regarding composition, the treatment of the components, 
and the antibodies used of the investigated LFDs, except for the Bionote LFD (Kang et al., 
2007).  
In other studies, evaluating the Bionote test, sensitivities and specificities of 85%-100% and 
93%-100% were observed respectively (Table 3). In the results presented here, a discrepancy 
in the sensitivities of the Bionote test was also seen between and within batches, 
considering the different sample sets, previous testing at the Friedrich-Loeffler-Institute (FLI) 
and the results from Italy. Although there are differences between the published studies, i.e. 
different samples and batches of the test used and test implementation and evaluation by 
different individuals, the simplicity of the test system should enable it to function 
independently from these factors. After all, the simple nature of the LFDs should be one of 
their strengths (O'Farrell, 2015).  
A very interesting feature of the LFDs first demonstrated here and later confirmed in 
another study (Lechenne et al., 2016), is that RNA can be stored in the used test strips for a 
longer period of time, i.e. six weeks. As test strips can be considered no longer infectious one 
hour after use, they could be sent to a laboratory for lyssavirus characterisation using RT-
PCR or sequencing. However, cooperation with a laboratory containing the necessary 
facilities is mandatory and results are not immediately available. An alternative would be a 
multiplex LFD which is able to differentiate between the lyssavirus species. As multiplexing 
on one test strip provides several challenges, separate strips with specific antibodies for the 
different lyssaviruses might be a solution (Li and Macdonald, 2016). This would on the other 
hand increase the cost for testing, as more LFDs are needed for rabies diagnosis. As there 
are often difficulties with the funding of rabies surveillance in developing countries, a single 
LFD with a broad reacting antibody for the detection of preferably all lyssaviruses might be 
the better option. In these regions the focus is on dog rabies surveillance and elimination, 
since most human rabies cases are dog-mediated. As more than 99% of rabies cases in 
terrestrial mammals are caused by RABV, the identification of the lyssavirus species is not a 
necessity for rabies elimination in these animals. One region where a multiplex LFD might be 
appropriate would be Africa, where phylogroup 2 lyssaviruses, i.e. MOKV and LBV, are 
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endemic. Since for both lyssaviruses infections of companion animals, i.e. cats and dogs, 
have been reported (Sabeta et al., 2007, Markotter et al., 2006), a LFD which is able to 
differentiate between phylogroups 1 and 2 would be useful, especially if a human exposure 
has occurred. 
Publication of the data presented here, resulted in an echo of the media, including a press 
release by the journal Public Library of Science Neglected Tropical Diseases (PLOS NTDs), 
which was picked up by other news agencies, i.e. ScienceDaily, Labmedica, Scimex, 
EurekAlert and the New York Times (McNeil Jr., 2016, Labmedica International staff writers, 
2016, PLOS Neglected Tropical Diseases, 2016, PLOS, 2016b, PLOS, 2016a). Furthermore, in a 
search for continued availability of LFDs used in this study in May 2017 only four out of the 
six LFDs were found, with two (Creative diagnostics, Biogen) apparently no longer available. 
An extended search for other commercially available LFDs using the keywords “rapid rabies 
test” resulted in the discovery of thirteen additional LFDs now commercially available 
(Appendix Table 1). However, there is hardly any information regarding their composition 
with sometimes confusing descriptions, e.g. what sample to use, if the tests aim at the 
detection of rabies antigen or antibodies, or mention of other infectious agents indicating 
copy and paste of the test description (see Table 4, No. 2, 4, 13). Still, the number of tests 
available highlight the interest in and need for a rapid test system for rabies diagnosis and 
prove that LFDs in general are promising candidates for field diagnosis of rabies. 
As mentioned previously, the development of a functional, i.e. sensitive, specific and 
reliable, LFD would greatly improve rabies surveillance and subsequent elimination in 
developing countries, but test development is only the first step. As far as information is 
provided within the manufacturer’s instruction, apart from Bionote, three further LFDs were 
developed for rabies diagnosis, which were never commercialized and can therefore not be 
acquired by countries in need (Ahmed et al., 2012, Kasempimolporn et al., 2011, Nishizono 
et al., 2008). Therefore, besides test development and extensive validation, collaboration 
with a company is important to make the test commercially available. 
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Conclusion: 
Rabies presents a human health threat which, although the elimination of dog-mediated 
rabies would reduce it immensely, can never be erased due to the presence of bat 
lyssaviruses. Since bat rabies elimination is not feasible for various reasons, monitoring bat 
lyssaviruses in the scope of preferably passive surveillance is the only option. This enables a 
regular assessment of bat lyssaviruses epidemiology and the resulting possible human health 
threat, and is therefore extensively performed in Germany. Furthermore, assessing the 
properties of the viruses themselves is of importance to identify and quantify possible 
sources and risks of transmission and infection. Elimination of dog-mediated human rabies is 
aimed to be achieved by 2030, but beforehand several major challenges, e.g. concerning 
rabies diagnosis, need to be overcome. 
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7.Summary 
Rabies, a zoonotic disease known since ancient times, is caused by lyssaviruses and almost 
always fatal once clinical signs develop. Although most of Europe, including Germany, is free 
of terrestrial rabies, bat rabies is still present. Surveillance in Europe showed that most bat 
rabies cases are caused by European bat lyssavirus 1 (EBLV-1). For this virus spill-over 
infections in various terrestrial mammals including humans have been described. Two 
genetic sublineages of EBLV-1 exist and a third one has been proposed. Furthermore, 
insertions and deletions were found in the genomes of selected isolates. Since it was proven 
for other lyssaviruses that genetic variation can have an impact on the pathogenicity of the 
respective isolates, it was investigated if the same is true for EBLV-1. Differences in the 
pathogenicity of investigated isolates were discovered after intranasal and intramuscular 
inoculation, although at the moment it is impossible to determine the exact cause. Upon 
comparison of the different inoculation routes, i.e. intracranial, intramuscular and intranasal, 
differences in the clinical signs of the mice as well as in the virus distribution within the brain 
were discovered.  
The isolates used in the pathogenicity study were obtained in the scope of passive 
surveillance, providing another example of the benefit of such programs. Furthermore, 
surveillance is important to assess the potential human health threat of endemic bat rabies 
by providing epidemiological data. Passive surveillance led to the detection of 362 bat rabies 
cases in Germany until 2016. The majority were caused by EBLV-1, but five cases of 
European bat lyssavirus 2 (EBLV-2) and six cases of Bokeloh bat lyssavirus (BBLV) were also 
discovered, including in 2015 the first case of BBLV in another bat species apart from its 
presumed reservoir host the Natterer's bat. Interestingly within the same year two 
additional cases of BBLV were found in Germany, doubling the number of BBLV cases there 
from three to six. Eight BBLV isolates were so far detected altogether and a division of the 
isolates into two genetic lineages A and B was possible. At the host level there is a massive 
distribution of virus to the peripheral organs. This sudden emergence of BBLV, despite 
similar surveillance intensity over the past years, is puzzling. 
The majority of human rabies cases are caused by rabid dogs and occur prominently in Asia 
and Africa, resulting in an estimated 59000 human deaths per year. In these regions rabies 
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surveillance is hindered by several factors including challenges in rabies diagnosis. Therefore, 
alternative test methods to the standard diagnostic tests for rabies were developed, 
including Lateral flow devices (LFDs), which have potential for field use. However, the 
comparison of six commercially available LFDs performed here revealed that the tests have 
major deficits regarding their sensitivity and reproducibility.  
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8.Zusammenfassung 
Die Tollwut ist eine zoonotische Erkrankung, die durch Lyssaviren verursacht wird, welche 
mit dem Auftreten klinischer Symptome fast immer tödlich endet. Obwohl große Teile 
Europas inklusive Deutschland frei von terrestrischer Tollwut sind, spielt die 
Fledermaustollwut in diesen Gebieten eine wichtige Rolle. Die 
Fledermaustollwutüberwachung in Europa hat gezeigt, dass das Europäische 
Fledermaustollwutvirus 1 (EBLV-1) für die meisten Fälle verantwortlich ist. Vereinzelte 
Infektionen anderer Tierarten und des Menschen wurden beschrieben. Während für EBLV-1 
zwei genetisch unterschiedliche Entwicklungslinien anerkannt sind, ist eine dritte derzeit 
noch in Diskussion. Bei einigen wenigen EBLV-1 Isolaten wurden bislang einzigartige 
Insertionen und Deletionen in bestimmten Bereichen des Genoms beschrieben. Wie für 
andere Lyssaviren bereits gezeigt wurde, können genetische Variationen die Pathogenität 
beeinflussen. Daher bestand ein wesentlicher Teil dieser Arbeit darin, herauszufinden, ob 
dies auch bei derartigen EBLV-1 Isolaten zutrifft. Unterschiede in der Pathogenität der 
untersuchten Isolate wurden nach intranasaler und intramuskulärer Inokulation von Mäusen 
gefunden. Allerdings ist unklar, welcher dieser genetischen Unterschiede dafür 
verantwortlich ist. Beim Vergleich der unterschiedlichen Inokulationsrouten, d.h. 
intrakranial, intramuskulär und intranasal, wurden Unterschiede im klinischen Bild der 
inokulierten Mäuse sowie der Virusverteilung im Gehirn gefunden.  
Die für die Pathogenitätsstudie verwendeten EBLV-1 Isolate wurden im Rahmen der passiven 
Fledermaustollwutüberwachung gefunden und stellen damit ein Beispiel für den Nutzen 
solcher Programme dar. Darüber hinaus ist die Überwachung und anschließende 
Auswertung epidemiologischer Daten eine wichtige Voraussetzung für die Risikobewertung 
hinsichtlich einer potentiellen Gefährdung des Menschen durch endemische 
Fledermaustollwut. Im Rahmen der passiven Überwachung wurden bis zum Jahr 2016 
insgesamt 362 Fledermaustollwutfälle in Deutschland diagnostiziert. Während EBLV-1 für 
den Großteil dieser Fälle verantwortlich war, entfielen fünf Fälle auf das Europäische 
Fledermaustollwutvirus 2 (EBLV-2) und sechs Fälle auf das Bokeloh Fledermaustollwutvirus 
(BBLV). Einer dieser durch BBLV verursachten Tollwutfälle wurde 2015 in einer anderen 
Fledermausart als dem vermuteten Reservoir, der Fransenfledermaus, gefunden. 
Interessanterweise trat innerhalb eines Jahres eine unerwartete Häufung von BBLV Fällen 
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auf. Insgesamt sind bislang acht BBLV-Isolate nachgewiesen worden, welche in zwei 
unterschiedliche Entwicklungslinien, A und B, eingeteilt werden können. 
Tollwütige Hunde sind für die überwältigende Mehrheit der schätzungsweise 59000 
humanen Tollwutfälle in Asien und Afrika verantwortlich. In diesen Regionen wird die 
Tollwutüberwachung stark durch gesundheitspolitische und infrastrukturelle Probleme, aber 
auch fehlende technische Ausrüstung und Engpässe in der Tollwutdiagnostik beeinflusst. Aus 
diesem Grund wurden Point-of-care Tests, wie z.B. Lateral flow devices (LFD), als alternative 
Verfahren zu standardisierten diagnostischen Tollwuttestmethoden entwickelt, die jedoch 
bislang nicht ausreichend validiert sind. Die vergleichende Evaluierung sechs kommerziell 
erhältlicher Tollwut-LFDs ergab, dass diese Tests große Defizite hinsichtlich ihrer Sensitivität 
und Reproduzierbarkeit aufweisen. 
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10.Appendix 
Appendix Table 1: Summary of other rapid rabies test for the detection of rabies virus 
antigen. 
 
 
No. Name Country Source 
1 
Dianotech Rapid 
Rabies Ag Test Card 
China http://www.lyncmed.com/product/997.htm  
2 
Raysonbio Rabies 
Virus Antigen Rapid 
Test Kit 
China 
http://www.globalsources.com/si/AS/Jiangsu-
Rayson/6008850358162/pdtl/Rabies-Virus-RV-
Antigen-Rapid-Test-Kit/1132150614.htm  
3 
Rohi Biotechnology 
Rabies Virus Ag Rapid 
Test 
China 
http://rohibio.en.alibaba.com/product/603873
45482-
802442170/Manufacturer_of_Rabies_Virus_A
g_Rapid_Test_with_ISO_certification.html  
4 
Finder Canine Rabies 
Virus (RBV) Antigen 
Test Strip 
China 
http://www-finderbio-com-
en.sell.ecer.com/pz6e0794a-canine-rabies-
virus-rbv-antigen-test-strip-colloidal-gold.html 
5 
Intas Rabies Antigen 
Rapid Test Kit 
India 
http://www.weiku.com/products/14615294/R
abies_Antigen_Rapid_Test_Kit.html 
6 
Diavetra Rabies 
antigen test 
India 
http://www.toboc.com/images/pdf/764982.p
df 
7 
LilliTest Rapid Rabies 
Ag Test Kit 
England 
http://diagnostics.lillidale.co.uk/wp-
content/uploads/2016/08/LilliTest-Rabies-Ag-
Test-Kit.pdf  
8 
Swissavans rabies 
antigen test Kit 
Switzerland 
http://www.swissavans.com/domains/swissav
ans_com/data/free_docs/RapidTests_PI_de.pd
f 
9 
InterMedical Rapid 
Test Device Rabies Ag 
Italy 
http://www.intermedical.it/en/products/veter
inary/ 
10 MINITEST Rabies Ag kit  
Austria/ 
France 
http://biomedica.eval3.css4you.at/fileadmin/d
ata/VetRapidTests_2011-
06_AT_CZ_HU_PL.pdf 
11 
Reagen rabies virus 
antigen rapid Test Kit 
USA 
http://www.bio-
equip.cn/enshow1equip.asp?equipid=58335&
division=2535  
12 
Medigen Rabies Ag 
Test Kit  
USA 
http://www.stallionpublishers.com/publicatio
ns/1122/p/medigen_one_step_rapid_test_kitv
2.pdf 
13 
Abgenome Ag Rapid 
Canine Rabies Virus 
Test Kit  
unknown 
https://www.dhgate.com/store/product/crv-
ag-rapid-canine-rabies-virus-test-
one/255686682.html  
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